May 12, 2026 • 47 mins
We trace how cellular senescence turns damaged cells into “zombies” that stay alive, stop dividing, and poison nearby tissue with the SASP inflammatory cocktail. We weigh what the best human trials actually show about senolytics and why the next wave of precision therapies may matter more than today’s supplement hype.
• cellular senescence as an active stress state, not “cells getting tired”
• the Hayflick limit, telomeres, and why senescence starts as tumor suppression
• SASP as the driver of tissue damage, bystander effects, and inflammaging
• antagonistic pleiotropy and why SASP can help early-life healing
• immunosenescence as the reason senescent cells accumulate with age
• senolytics and survival pathways that keep senescent cells alive
• dasatinib plus quercetin and the logic of hit-and-run dosing
• Mayo Clinic data suggesting benefits depend on baseline senescent burden
• fisetin osteoarthritis trial and how bioavailability can erase lab promise
• senomorphics that silence SASP when cells are “load bearing”
• precision approaches like suicide gene therapy and senescence-targeted CAR-T
• the “psychoage” question of what longer healthspan does to human urgency
This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice.
Never miss an episode—subscribe on your favorite podcast app!
Listen
Watch
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
SPEAKER_02 (00:00):
Right now, inside your body, a microscopic
rebellion is taking place.
I'm totally serious.
Like, as you're listening tothis right now, certain cells in
your tissues have sufferedmassive DNA damage.
But instead of doing thehonorable thing and just, you
know, dying to make room forhealthy cells, they've gone
rogue.
SPEAKER_00 (00:19):
They really have.
SPEAKER_02 (00:20):
Right.
They've raised these biologicalshields, locked themselves deep
into your tissue, and juststarted actively spewing toxic
sludge at their neighbors.
SPEAKER_00 (00:28):
Aaron Powell It is a it's a genuinely terrifying
biological reality when youphrase it exactly like that.
But honestly, it's highlyaccurate.
SPEAKER_02 (00:36):
I know, right?
You've probably seen theheadlines floating around.
They're literally everywhere.
Things like uh zombie cells inyour organs or some billionaire
tech bro spending millions tocure aging and live to be 150.
SPEAKER_00 (00:48):
Aaron Powell Oh, the tech bro headlines are endless
right now.
SPEAKER_02 (00:50):
Endless.
And it sounds like pure sciencefiction, like the plot of a bad
zombie movie where theapocalypse just starts in a
petri dish.
But today we are cuttingstraight through all of that
internet hype.
We're going to talk about whatis actually happening in your
biology right this second.
And trust me, the actual scienceis way weirder and way more
fascinating than the clickbaitmakes it sound.
SPEAKER_00 (01:11):
Trevor Burrus, Jr.
It really is.
The reality of the biology hereis just it's so much more
complex than, you know, takethis magical biohacker pill and
live forever.
SPEAKER_01 (01:19):
Yeah.
SPEAKER_00 (01:20):
Aging isn't just this abstract concept of time
passing.
You know, it's not just thecalendar flipping over and your
body suddenly deciding to ache.
It's driven by very distinct,physical, measurable biological
mechanisms.
And today, we are zeroing in onone of the absolute biggest
culprits, a phenomenon calledcellular senescence.
SPEAKER_02 (01:39):
Aaron Ross Powell Exactly.
And that is the mission for thisdeep dive.
We have a massive stack ofsources to go through with you
today.
We're talking human clinicaltrials, real human data, not
just mice out of Georgia, thecountry, not the state and the
Mayo Clinic.
SPEAKER_00 (01:52):
Aaron Powell The human data is where things get
really interesting.
SPEAKER_02 (01:55):
Totally.
We've got biotech startup pressreleases, deeply dense
physiological reviews, all ofit.
And we are going to figure outwhat these so-called zombie
cells actually are, what thesedrugs called synolytics actually
do, and most importantly,whether this science is actually
ready for you to use, or ifyou're just, you know, flushing
(02:16):
your money down the toilet,buying expensive powders online.
SPEAKER_00 (02:19):
Which, spoiler alert, a massive amount of
people are currently doing.
But I think before we even touchon the drugs that supposedly
clear these things out, wereally have to ground this in
the biology.
We need to unpack what a zombiecell actually is.
Because your body doesn't justspontaneously generate monsters
to ruin your life.
There is a deeply ingrainedevolutionary reason they exist.
(02:40):
Aaron Powell Right.
SPEAKER_02 (02:41):
So let's get into it.
Because I hear a term likecellular senescence, and my
brain just defaults to likecells getting old and tired and
eating a nap.
SPEAKER_00 (02:49):
Right, the fatigue theory.
SPEAKER_02 (02:50):
Yeah, like they just run out of gas.
But it's way more aggressivethan that.
It's an active state.
SPEAKER_00 (02:55):
It is an incredibly active state.
It's not passive decay at all.
So let's step back and look atthe basics of how your body
maintains itself.
In normal, healthy tissue, yourcells divide.
They replicate to replace old,damaged, or dead tissue.
You get a cut, your skin cellsdivide to heal it.
But, and this was a massiveparadigm shift in biology, they
(03:18):
cannot do this forever.
SPEAKER_02 (03:19):
Wait, really?
I thought that was the wholepoint of cells.
They just keep copyingthemselves.
SPEAKER_00 (03:22):
For a long time, scientists thought that too.
Back in the early 20th century,there was this famous, though
highly flawed experiment byAlexis Carroll, where he claimed
to keep chicken heart cellsdividing in a lab for decades.
SPEAKER_01 (03:36):
Oh, wow.
SPEAKER_00 (03:36):
Yeah, people thought cells were essentially immortal.
But then in 1961, theseresearchers, Leonard Hayflick
and Paul Moorhead, completelyshattered that myth.
They discovered that human cellscultured in a lab have a strict
hardwired limit on how manytimes they can divide.
It's called the Hayflick limit,usually around 40 to 60
divisions for a human cell.
SPEAKER_02 (03:55):
Aaron Powell So they literally just hit a wall, like
a biological kill screen in avideo game.
SPEAKER_00 (03:59):
Aaron Ross Powell Exactly.
And the mechanism behind thiswall is fascinating.
It largely comes down totelomeres.
SPEAKER_02 (04:05):
Aaron Powell Oh man.
Okay.
I know exactly where this isgoing.
Every biology textbook I everread uses that same awful
metaphor for telomeres.
The little plastic caps at theend of your shoelaces.
SPEAKER_00 (04:16):
Trevor Burrus, Jr.
It's everywhere.
SPEAKER_02 (04:17):
Trevor Burrus, I always hated that.
It never made sense to me.
What happens when the cap fallsoff, the DNA shoelace just frays
into strings?
SPEAKER_00 (04:24):
Aaron Powell I agree.
The shoelace analogy isincredibly overused and honestly
functionally misleading.
A much better way to think abouta telomere is like a prepaid
biological debit card for celldivision.
SPEAKER_02 (04:37):
Trevor Burrus, oh I like that.
Okay, so every time the celldivides, it swipes the card.
SPEAKER_00 (04:41):
Aaron Ross Powell Exactly.
Every time a cell replicates itsDNA to divide, the machinery
that copies the DNA can't quitereach the very, very end of the
strand.
So a tiny piece of the telomere,which is just a repeating
sequence of junk DNA thatdoesn't code for anything
important, is left off.
It's the transaction fee.
SPEAKER_02 (04:57):
Right.
SPEAKER_00 (04:58):
You swipe the card, you lose a little bit of the
balance, the telomere getsphysically shorter.
SPEAKER_02 (05:01):
Okay, I'm tracking.
So you keep dividing, you keepswiping the card, and eventually
the balance hits zero, carddecline.
SPEAKER_00 (05:08):
Card decline.
The telomere becomes criticallyshort.
And when that happens, thecell's internal sensors freak
out.
They recognize that if theydivide again, they won't be
cutting into junk DNA.
They'll be cutting intoessential crucial genes.
SPEAKER_01 (05:21):
Oh, it makes sense.
SPEAKER_00 (05:22):
The cell realizes I am severely damaged.
If I replicate now with brokenDNA, I might mutate.
I might become a cancer cell.
SPEAKER_02 (05:30):
Ah.
So the climate isn't a flaw,it's a safety mechanism.
It's slamming the brakes beforethe car goes off the cliff.
SPEAKER_00 (05:36):
Precisely.
It's an incredibly elegant tumorsuppressor mechanism.
And usually when a cell reachesthat state or if it experiences
severe acute stress like amassive dose of radiation or
intense oxidative stress orcertain viral infections, it is
supposed to do the biologicallynoble thing.
It triggers a programmedself-destruct sequence.
SPEAKER_02 (05:55):
Aoptosis.
SPEAKER_00 (05:56):
Yes, apoptosis.
The cell neatly and quietlypackages its internal components
into these little lipid vesiclesand it sends out a signal to the
immune system.
Macrophages, which areessentially your body's garbage
trucks, swoop in and eat thevesicles.
SPEAKER_02 (06:12):
Just cleans it right up.
SPEAKER_00 (06:14):
It's clean, it doesn't cause inflammation, and
the surrounding tissue iscompletely unharmed.
That is how a healthy body staysyoung and functional.
SPEAKER_02 (06:21):
But and I'm guessing this is the crux of the whole
deep dive.
Sometimes they don't do thenoble thing.
SPEAKER_00 (06:26):
Sometimes they absolutely refuse to die.
SPEAKER_02 (06:28):
They just say no.
They override the self-destruct.
SPEAKER_00 (06:31):
They override it completely.
They arrest their cell cycle,meaning they permanently,
irreversibly stop dividing, butthey stay alive, they dig in,
they turn on these highlyspecific, highly robust
anti-apoptotic pathways.
Basically, they raise internalblast shields to resist their
own death signals.
SPEAKER_02 (06:48):
Dude, that is deeply creepy.
SPEAKER_00 (06:50):
And that that is what a senescent cell is.
That is your zombie.
It's not dead, it refuses todie, but it is entirely stripped
of its normal, healthy function.
SPEAKER_02 (06:58):
It just sits there taking up space, refusing to
clock out.
But wait, if they're justsitting there, not dividing, why
are they such a massive problem?
Like if I have a zombie cellparked in my bicep or my liver
and it's not turning intocancer, who cares?
Why is it driving systemicaging?
SPEAKER_00 (07:14):
Aaron Powell Because they aren't just sitting there
quietly taking up space.
This is the biggestmisconception about senescence.
They are highly, franticallymetabolically active and they
are screaming.
Screaming.
Chemically screaming.
And this introduces a piece ofjargon that is absolutely
central to everything we'retalking about today.
It's an acronym, S-A-S P.
(07:35):
It stands for the SenescenceAssociated Secretary Phenotype.
SPEAKER_02 (07:38):
S-A-S-P.
Honestly, looking at the papers,phenotype feels way too
clinical.
I'm just going to call it ToxicZombie Sludge because when you
read what it actually does tothe surrounding tissue, it
sounds like radioactive sludge.
SPEAKER_00 (07:49):
You know, toxic zombie sludge is scientifically
crude, but it is functionallybrilliant because it really
captures the destructive natureof it.
But to give you the precisebiological breakdown, this
sludge is a highly complex,continuously secreted cocktail
of proteins.
SPEAKER_02 (08:06):
Okay, what kind of proteins?
SPEAKER_00 (08:07):
We are talking about pro-inflammatory cytokines,
specifically things likeinterleukin-6 or IL6 and
interleukin 8.
We're talking about chemokines,which summon immune cells to the
area.
We're talking about heavy-dutygrowth factors.
And worst of all, proteas.
SPEAKER_02 (08:23):
Wait, remind me what a protease does.
It breaks things down, right?
SPEAKER_00 (08:26):
Yes.
Proteases are enzymes thatliterally chew up proteins.
Matrix metal proteinasesspecifically degrade the
extracellular matrix, thestructural scaffolding that
holds your tissues together.
SPEAKER_02 (08:38):
So they're actively destroying the neighborhood.
SPEAKER_00 (08:41):
They are.
SPEAKER_02 (08:41):
It's like a bad tenant.
They park on the lawn, theyrefuse to leave, and then they
just start dumping battery acidon the grass, throwing trash
everywhere, and blasting loudmusic all night to keep everyone
else awake.
SPEAKER_00 (08:52):
That is a phenomenal analogy.
The tissue degradation is veryreal, but it gets even worse
than the battery acid on thelawn.
Because of the specific natureof this SCSP sludge, it doesn't
just degrade the scaffolding.
It actually infects theneighboring healthy cells.
Researchers call it thebystander effect.
SPEAKER_02 (09:12):
Hold on.
You're saying the sludge fromthe zombie hits a perfectly
healthy cell next door and doeswhat?
Does the healthy cell die?
SPEAKER_00 (09:19):
No, it doesn't die.
The inflammatory signals,especially the cytokines and the
reactive oxygen species in theSSP, cause immense stress to the
healthy neighbor.
And that stress forces thehealthy cell to also trigger its
blast shields, lock its cellcycle, and become senescent.
SPEAKER_02 (09:36):
No way.
It actually turns them intozombies too.
SPEAKER_00 (09:39):
It does.
SPEAKER_02 (09:39):
It's a literal zombie bite.
One gets infected, turns, andthen immediately starts biting
the neighbors.
That is insane.
It's an exponential infectionmodel.
SPEAKER_00 (09:47):
It is exactly an infection model, just driven by
chemistry rather than a virus.
And as this chain reactionspreads through a tissue, it
drives a massive systemicproblem that researchers have
termed inflammaging.
SPEAKER_02 (09:59):
Inflammaging.
Inflammation plus aging.
SPEAKER_00 (10:01):
Exactly.
It's this chronic, low-grade,simmering systemic inflammation
that creeps up on all of us aswe get into our 40s, 50s, and
beyond.
If you look at the sources, themedical consensus is crystal
clear.
This inflammaging, driven at itscore by the SAP sludge, is
fundamentally linked to almostevery major disease of aging.
SPEAKER_02 (10:23):
Like what specifically?
SPEAKER_00 (10:24):
Cardiovascular disease, atherosclerosis, type 2
diabetes, neurodegeneration likeAlzheimer's and Parkinson's,
osteoarthritis, and ironicallylate-life cancers.
SPEAKER_02 (10:35):
Wait, ironically, because you just said senescence
evolved to stop cancer.
SPEAKER_00 (10:38):
But it does initially.
But remember that SASP cocktail.
It's full of growth factors andenzymes that chew up the tissue
matrix.
If a legitimate cancer cell doesmanage to form nearby, that
degraded tissue and those growthfactors provide the perfect
fertile soil for a tumor torapidly grow and metastasize.
It's a tragic paradox.
SPEAKER_02 (10:56):
Okay, I have to push back here.
Because my brain is spinning.
SPEAKER_00 (10:58):
Go for it.
SPEAKER_02 (10:59):
If these zombie cells are so incredibly toxic,
if they literally secrete asludge that melts our tissues,
infects other cells, and causesour bodies to break down and
die, why did evolution let themexist?
Why didn't our bodies justevolve to instantly nuke any
cell that turns senescent?
It seems like a massive glaringdesign flaw in the human
blueprint.
SPEAKER_00 (11:20):
That is the million-dollar question in
gerontology.
And the answer lies in a conceptcalled antagonistic pleiotropy.
SPEAKER_01 (11:27):
Okay, that is a mouthful.
Unpack antagonistic pleiotropyfor me.
SPEAKER_00 (11:31):
It sounds intimidating, but the concept is
simple.
It refers to a biologicalfeature or a gene that is highly
beneficial when you are youngand trying to survive, but
becomes actively detrimentalwhen you are old.
You have to remember howevolution works.
Right.
Evolution only really caresabout one thing: getting you to
reproductive age and keeping youalive long enough to raise your
offspring.
What happens to your joints oryour brain at age 70 or 80,
(11:54):
evolution doesn't care.
There's no evolutionary pressureto fix problems that only kill
you after you've passed on yourgenes.
SPEAKER_02 (12:01):
So you're saying the zombie sludge, the SAP, is
actually good for you whenyou're young?
SPEAKER_00 (12:06):
It is absolutely crucial for your survival.
Here's the twist that blowspeople's minds.
When you're young, say you're ahealthy 20-year-old and you get
a severe cut or a muscle injury,cells in that specific area
temporarily become senescent.
They rapidly pump out that SAPsludge.
But in a young, healthy body,that acute burst of inflammation
(12:26):
isn't a chronic burn.
It's a massive glaring signalflare.
SPEAKER_02 (12:30):
Like calling 911.
SPEAKER_00 (12:31):
Exactly.
Tells your immune system, hey,massive damage here.
Send the macrophages, send therepair stem cells immediately.
The SAP actually orchestratesthe wound healing process.
It promotes tissue regeneration.
Oh wow.
And even crazier, duringembryonic development, when you
are literally a fetus growing inthe womb, transient senescent
cells use their SAP to helpsculpt the growing tissues.
(12:54):
They create the temporaryscaffolding, signal the growth,
and then gracefully clear out.
SPEAKER_02 (12:58):
Wait, wait, wait.
We use zombie sludge to grow asembryos, that's how we develop.
SPEAKER_00 (13:02):
We do.
Without senescence, you wouldn'tdevelop properly.
The mechanism is a masterpieceof biology.
The problem isn't that senescentcells exist.
The system works perfectly whenwe are young.
The cell gets damaged, turnssenescent, shoots up this view
flare, stops itself frombecoming cancer, and then the
immune system, the garbagetrucks, sees the flare, swoops
in, and eats the senescent cell.
(13:24):
Tissue healed, danger averted.
SPEAKER_02 (13:26):
Okay, so the system is a closed loop.
What breaks?
Why do they accumulate whenwe're older?
SPEAKER_00 (13:30):
What breaks is the immune system itself.
As we age, our immune systemundergoes a parallel process
called immunosinescence.
The garbage trucks get tired,the macrophages become less
efficient at recognizing the SACflares, the natural killer cells
get sluggish.
SPEAKER_02 (13:45):
Oh, so the dispatcher is ignoring the 911
calls.
SPEAKER_00 (13:49):
Precisely.
The senescent cells are stillforming because your cells are
still dividing, getting stressedby toxins, poor diet, UV
radiation, simple time, and theyare still shooting at their SAC
flares.
But the immune system just stopsshowing up to clear them out.
SPEAKER_02 (14:01):
So they just sit there, multiplying.
SPEAKER_00 (14:02):
They accumulate.
And because of that bystandereffect we talked about, the
longer they sit there, the morehealthy neighbors they infect.
The inflammation transitionsfrom being a helpful, acute
alarm bell into a chronic,low-level, relentless burn.
And that chronic burn is whatslowly destroys your tissue
architecture over decades.
SPEAKER_02 (14:22):
Wow.
Okay.
That makes perfect sense.
It's a failure of clearance, nota failure of design.
So the immune system is slackingoff, the zombies are biting the
neighbors, the tissue is fillingup with sludge, which perfectly
leads us into the logical nextstep.
If our bodies can't naturallyclear them out anymore, how do
we intervene?
How do we build an artificialgarbage truck to flush them out?
SPEAKER_00 (14:43):
And this brings us to the advent of senolytics.
The drugs designed to do exactlywhat our immune system forgot
how to do.
SPEAKER_02 (14:49):
Right.
Let's talk about killing them.
Because if you want to kill azombie, you have to know how
it's surviving.
You mentioned earlier they haveblast shields.
SPEAKER_00 (14:56):
Yes.
To understand a senalytic drug,you have to understand the S
keeps senescent cellanti-apoptotic pathway.
SPEAKER_01 (15:04):
The blast shields.
SPEAKER_00 (15:05):
Exactly.
When researchers first startedtrying to kill these cells, they
realized it was incrediblydifficult.
The cells were stubborn.
So they did these massivebiointraumatic screens.
They looked at the transcriptum,meaning they looked at exactly
which genes were turned on andwhich were turned off in a
senescent cell compared to ahealthy cell.
Right.
And they found that senescentcells heavily, desperately rely
(15:28):
on certain survival networks,specifically families of
proteins like the BCL2 family orcertain tyrosine kinases.
SPEAKER_02 (15:35):
Okay, break those down for me.
What is a tyrosine kinase doingin this context?
SPEAKER_00 (15:39):
Think of a tyrosine kinase, like a highly specific
switchboard operator inside thecell.
Its job is to take signals,often survival signals, and pass
them down the chain to tell thecell, keep the blast shields up,
do not trigger apoptosis, stayalive.
Senescent cells have theseswitchboards jammed in the on
position.
They are completely dependent onthese specific pathways to
(16:01):
survive the massive internalstress of being a zombie.
SPEAKER_02 (16:04):
So they're basically on life support.
SPEAKER_00 (16:05):
Exactly.
They are teetering on the edgeof self-destruction, only kept
alive by these hyperactive SDFCshields.
So the theory was born.
What if we use a drug to justtemporarily jam the switchboard?
Turn the shield off for just aminute.
A healthy cell wouldn't carebecause a healthy cell isn't
under massive stress, it doesn'tneed emergency shields to
(16:27):
survive.
SPEAKER_02 (16:28):
But a senescent cell-If you pull the plug on its
life support, even for a second,the whole thing crashes and it
dies?
SPEAKER_00 (16:34):
Yes, it's pushed over the edge into apoptosis, it
finally dies.
Drugs that do this are calledsenolytics.
They selectively induce death insenescent cells while leaving
healthy cells entirely alone.
And the fascinating thing is,when researchers figured this
out, they didn't have to inventa completely new drug from
scratch.
The very first wave ofsynolytics were compounds we
(16:54):
already had in the pharmacy inthe grocery store.
SPEAKER_02 (16:56):
Yes.
Okay, let's talk about the mostfamous combo in this space,
because this is where the humandata gets wild.
D plus Q.
SPEAKER_00 (17:03):
Dacidamib and Quircetin.
SPEAKER_02 (17:04):
Right.
So D is docetamib, which, if I'mreading this right, is an
intense FDA-approved leukemiadrug.
It's literal chemotherapy.
And Q is quercetin, which is anatural flavonoid plant
compound.
You can buy it in a plasticbottle at the vitamin Ile.
It's in apples, onions, capers.
How did they end up pairing aheavy-duty cancer drug with an
(17:27):
apple extract?
SPEAKER_00 (17:28):
It comes back to those switchboards.
Docitative is a broad spectrumtyrosine kinase inhibitor.
It's very good at jammingcertain survival signals,
specifically theefferin-dependent pathways, but
it doesn't hit all of them.
Quircetin, on the other hand,inhibits completely different
survival pathways like PI3K andcertain serpents.
Neither one of them is strongenough to clear out all types of
senescent cells on their own.
SPEAKER_02 (17:49):
But together cover each other's blind spots.
SPEAKER_00 (17:51):
Precisely.
Together, they hit multiple SCOAshields simultaneously across
different tissue types.
It was the ultimate one-twopunch.
And the preclinical data in micewas absurd.
It extended their lifespan,rejuvenated their cardiovascular
systems, but mice are mice.
The real question was whathappens in a human?
SPEAKER_02 (18:07):
Which brings us to the Republic of Georgia trial.
This was a 2019 clinical trial,and reading the methodology of
this study honestly blew mymind.
So they took 64 men, middle agedto older, the average age was
around 53, and they gave themthis D plus Q combo.
But here is the part that Ifound so crazy the dosing
(18:27):
schedule.
They didn't put them on a dailypill.
They gave them 50 milligrams ofdecetinib and 500 milligrams of
quercetin once a day for justfive days, and then they stopped
completely.
SPEAKER_00 (18:40):
This is a crucial concept in senotherapeutics.
It's called a hit and run dosingstrategy.
Think about the biology.
Senescent cells do not divide,they can't multiply.
So if you go in with a senolyticstrike team and clear out, say
30% of the zombies over fivedays those cells are gone, it'll
take weeks, maybe months, forthe natural stresses of life to
accumulate a new batch ofsenescent cells.
SPEAKER_02 (19:01):
So you don't need to suppress the pathway constantly.
SPEAKER_00 (19:05):
Exactly.
And that is incredibly fortunatebecause as you mentioned,
dustatinib is a chemotherapydrug.
If you take it every day formonths, it has massive side
effects, immunosuppression,bleeding, severe fatigue.
But a five-day pulse, the sideeffects are minimal.
SPEAKER_02 (19:21):
Okay, so five days of pills, then they waited 21
days, three full weeks.
The drugs are completelymetabolized, long gone from
their bloodstream, and then theytested them.
They had these guys do a stairascending test.
And this isn't just can you walkupstairs?
They are hooking them up toblood pressure monitors, timing
their endurance, seeing howtheir cardiovascular system
(19:42):
handles the acute stress ofclimbing four flights, and the
results The results were aprofound proof of concept.
Weeks after the drugs were gone,these 53-year-old men had
significantly improved physicalendurance.
Their times were faster.
But the craziest part was theblood pressure.
Their systolic blood pressuredropped, and their vitals
stabilized way faster after theexercise.
(20:02):
I need you to explain the howhere.
How does clearing out somerandom zombie cells three weeks
ago suddenly make a guy's bloodvessels work better today?
SPEAKER_00 (20:10):
It's all mechanical, driven by the removal of the
SASP.
Remember when we talked aboutthe proteases and the toxic
sludge, the enzymes that chew upthe extracellular matrix?
SPEAKER_02 (20:20):
Yeah, the ones destroying the neighborhood
scaffolding.
SPEAKER_00 (20:22):
Right.
Your blood vessels rely on aprotein called elastin to remain
stretchy and flexible.
That flexibility is whatregulates your blood pressure.
When your cardiovascular systemis loaded with senescent cells,
the constant bath of SAPproteases literally chews up
that elastin.
The blood vessels become stiff.
Stiff vessels mean high bloodpressure.
SPEAKER_01 (20:43):
Oh that is crazy.
SPEAKER_00 (20:45):
When the D plus Q pulsed through their system, it
triggered apoptosis and afraction of those senescent
cells in the endothelial liningof the vessels.
The cells died, the macrophagescleared the debris, and suddenly
the SSA sludge vanished.
The proteases stopped chewing upthe elastin.
The vessels rapidly regainedtheir natural elasticity, which
mechanically lowered the bloodpressure.
And on top of that, without thesystemic inflammation,
(21:07):
practically everyone in theactive D plus Q group reported
feeling a literal lightness inthe joints the very next day.
SPEAKER_02 (21:13):
Dude, that is unbelievable.
So it's not a stimulant, it'snot masting a symptom, it's
structurally repairing thetissue by removing the toxic
variable.
If I'm a listener right now, myimmediate thought is: okay,
where do I get a prescriptionfor DAS at nib?
I want my joints to feel lighttomorrow.
SPEAKER_00 (21:30):
And that is exactly where I need to step in and
throw a massive bucket of coldwater on the hype.
Because while the Georgian trialis incredibly exciting, science
is never just one study.
One study is an anomaly,multiple studies are data.
We have to look at the MayoClinic trial that was also in
our sources because this addssome very dry, very necessary
clinical reality to theconversation.
SPEAKER_02 (21:51):
All right, hit me with the reality check.
SPEAKER_00 (21:53):
The Mayo Clinic conducted a phase two,
randomized placebo controlledtrial using the exact same D
plus Q.
Combination, the same protocol.
But this time they tested it on60 healthy postmenopausal women.
SPEAKER_02 (22:06):
Why specifically postmenopausal?
SPEAKER_00 (22:08):
Because of estrogen.
When women go through menopause,estrogen levels plummet.
Estrogen is heavily involved inregulating bone metabolism.
Without it, bone resorption, thebreaking down of bone,
accelerates, which is whyosteoporosis is such a massive
risk.
And cellular senescence in thebone marrow is a huge driver of
this.
The senescent cells secrete SESPthat hyperactivates osteoclasts,
(22:31):
the cells that eat bone.
So the Mayo Clinic wanted to seeif we give these women D plus Q,
can we kill the senescent cellsand improve their bone formation
markers?
SPEAKER_02 (22:42):
Okay, that makes total sense.
So they tracked their bonemarkers.
What happened?
Did it work?
SPEAKER_00 (22:46):
Well, yes and no.
It did have a beneficial effecton bone formation markers like
P1MP, it reduced boneresorption, it did biologically
what it was supposed to do.
But, and this is a massive,highly critical, but when they
dug into the data, they found itonly benefited the women who
already had a significantly highbaseline burden of senescent
cells.
SPEAKER_02 (23:04):
Wait, really?
Only the ones with a highburden.
SPEAKER_00 (23:06):
Yes.
They measured the senescenceburden before the trial started.
If a woman had a relatively lownumber of senescent cells to
begin with, if her biologicalage was doing okay, the D plus Q
did virtually nothing for herbone health.
The markers barely moved.
SPEAKER_02 (23:23):
Oh, so it's not a prophylactic.
It's not a magic anti-agingvitamin that just buffs your
stats.
SPEAKER_00 (23:29):
Not at all.
Dr.
Sundit Kosla, who is a brilliantresearcher and the senior author
from the Mayo Clinic on this,gave a very stark warning about
this exact dynamic.
He pointed out that there aretens of thousands of people out
there right now reading theheadlines, buying commercial
coracetin online, and taking itevery single day as an
anti-aging supplement.
But his point is foundational.
(23:50):
If you don't actually have ahigh burden of senescent cells
in your tissues, taking asenolytic won't do anything for
you.
SPEAKER_02 (23:56):
It's like taking a highly potent weed killer,
walking out to a perfectlymanicured lawn that doesn't have
a single dandelion on it, andjust spraying chemicals
everywhere.
You're not making the grasshealthier, you're just pouring
poison on a healthy lawn for noreason.
SPEAKER_00 (24:08):
That is the perfect analogy.
If there are no zombies to kill,the zombie-killing drug does not
make you younger.
And it's not just useless, itcarries risk.
Taking high doses of kinaseinhibitors, even natural ones
when you don't need them, isjust asking for off-target side
effects.
You're jamming cellularswitchboards that might actually
need to be on.
SPEAKER_02 (24:28):
Right, because healthy cells need those
pathways too.
SPEAKER_00 (24:31):
Exactly.
Koslan noted that people withaccelerated aging conditions,
like cancer survivors who wentthrough heavy chemotherapy,
chemo massively induces cellularsenescence, which is why chemo
survivors often suffer fromearly frailty and heart issues.
Or people with severe obesity orprogeroid syndromes, those
people have massive zombieburdens.
(24:52):
They might benefit immenselyfrom D plus Q.
But a relatively healthy40-year-old taking kerosetin
every morning hoping to live to120, you're probably just making
incredibly expensive urine.
SPEAKER_02 (25:03):
Okay, if you're listening to this and looking at
that bottle of supplements onyour kitchen counter, you might
be feeling a little betrayedright now, which makes this the
perfect time to talk about theabsolute king of the supplement
hype cycle right now, physicin.
SPEAKER_00 (25:15):
Yes.
We absolutely have to talk aboutphysiotin.
SPEAKER_02 (25:18):
Because if you go online to any biohacking forum
or listen to certainoptimization gurus, physicin is
the golden child.
It's another natural flavonoid,very similar to quercetin.
You find it naturally instrawberries, apples,
persimmons.
And the hype didn't come out ofnowhere.
In petri dishes, invitrofeasitin looked like an
absolute miracle.
It looked like a highly potentsynolytic, maybe even better and
(25:40):
safer than the D plus Q combo,and you don't need an oncologist
to prescribe it to you, sopeople are buying it in bulk.
But our stack of sourcesincludes a very recent, highly
rigorous clinical trial from theStedman Philippon Research
Institute in Colorado, and thistrial is a total wake-up call.
SPEAKER_00 (25:57):
It really is.
This was a phase one and tworandomized, double-blind,
placebo-controlled trial.
That is the absolute goldstandard of clinical research.
No bias, no guessing.
SPEAKER_02 (26:08):
Exactly.
Let's break down the setup.
They took 74 subjects, rangingfrom 40 to 80 years old, who all
had radiographically confirmedosteoarthritis in their knees.
We are talking severe,bone-on-bone, painful joint
degradation.
And the biological rationalehere is rock solid.
We know from extensiveliterature that osteoarthritic
(26:28):
joints are basically ground zerofor senescence.
The cartilage is absolutelypacked with senescent
chondrocytes, and the SSPinflammation is what drives the
pain and the cartilage isdestruction.
SPEAKER_00 (26:38):
So the setup is pristine.
You have a localized, highlyburdened target area.
SPEAKER_02 (26:43):
Right.
So they split the group, halfget a placebo, half get oral
physicin.
And the dosing protocol wasintense.
They gave them 20 milligrams perkilogram of body weight.
So for an average guy, that'slike taking a massive fistful of
capsules.
They did it for two consecutivedays, then 28 days off.
The hit and run strategy again,they did three full cycles of
this, and then they trackedthese patients for an entire
year.
And they didn't just ask, how doyour knees feel?
(27:05):
They did deep metric tracking.
They used MRI T2 mapping.
SPEAKER_00 (27:09):
Which, for context, is an advanced imaging technique
that allows you to see themicroscopic water content and
collagen integrity inside thecartilage.
It shows you the actualstructural health of the tissue,
not just the gross bone gap.
SPEAKER_02 (27:22):
Thank you.
Yes.
They did T2 mapping, they didthe WLMAC pain and stiffness
surveys, they did 40-meter fastwalk tests, timed up and go
tests.
They measured literally everyfunctional metric you can think
of.
SPEAKER_00 (27:34):
Aaron Powell And what did the year of data
reveal?
SPEAKER_02 (27:36):
Total, absolute failure.
SPEAKER_00 (27:37):
Aaron Powell Completely null results across
the board.
SPEAKER_02 (27:40):
Aaron Powell I was reading the graphs and the
source data, and it's almostcomical in a dark way.
The trend lines for the Fissetingroup and the placebo group are
practically glued together.
No significant differences inthe MRI cartilage scans.
The cartilage kept degrading atthe same rate.
No difference in pain reduction.
No difference in physicalfunction, knee strength, or gate
speed.
(28:00):
Honestly, reading it made me abit angry.
Because people are dropping realcash on this stuff, they are
popping these massive doses ofpills, and it's doing literally
nothing in a human body.
SPEAKER_00 (28:10):
It is deeply frustrating, but it is a harsh,
necessary lesson intranslational medicine.
And the lesson is this.
Just because a moleculesuccessfully assassinates a
zombie cell in a perfectlycontrolled artificial
water-based environment like apetri dish, does not mean that
swallowing a plastic capsule ofit will fix your biological
hardware.
SPEAKER_02 (28:28):
Okay, so unpack the why here.
If fecetin is a proven sanolyticin the lab, why did it fail so
spectacularly in the humans?
Did they not use a high enoughdose?
SPEAKER_00 (28:37):
It's not a dosage issue.
It fundamentally comes down topharmacokinetics, specifically a
concept called bioavailability.
Ficetin, in its pure, naturalmolecular form, is highly,
highly hydrophobic.
It actively repels water.
SPEAKER_02 (28:51):
Like trying to mix olive oil into a glass of tap
water, it just clumps up andseparates.
SPEAKER_00 (28:55):
Exactly.
Now think about your digestivesystem.
Your stomach acid, the mucosallining of your intestines, your
bloodstream, your body, isoverwhelmingly water.
When you swallow pureficitinpowder, it hits that watery
environment and struggles todissolve.
And even if a little bit getsabsorbed to the gut lining, it
immediately hits the liver.
(29:15):
The liver's entire job is tofilter out foreign, poorly
soluble compounds.
It undergoes what's calledmassive first-pass metabolism.
The liver shreds the cissetinand excretes it before it ever
gets a chance to circulate inthe blood, let alone penetrate
the dense vascular tissue of thesynovial fluid inside a knee
joint.
SPEAKER_02 (29:33):
So the physicin wasn't failing to kill the
zombie cells, it just never evenreached the battlefield.
It was intercepted at theborder.
SPEAKER_00 (29:39):
That is the most medically probable explanation.
Swallowing pure fysitin is liketrying to wash your car with a
sponge wrapped in duct tape.
The soap is in there, but itcan't get out to do the work.
And this highlights a massive,foundational lesson for anyone
interested in longevity science.
Delivery mechanisms matter justas much, if not more, than the
(30:00):
drug itself.
You could have the greatest,most lethal biochemical warhead
in the world, but if you do nothave a missile guidance system
that can successfully deliver itto the target tissue, the
warhead is completely useless.
SPEAKER_02 (30:12):
Man, that is a brutal reality check.
And the researchers in the studywere pretty clear about this,
right?
They didn't say the concept ofsynolytics is dead.
They just said this specificoral formulation of physicin is
a dead end.
SPEAKER_00 (30:23):
Correct.
They are currently looking intoliposomal physicin, or injecting
it directly into the joint.
But the oral supplement you buyonline, the data says it's
functionally inert for yourknees.
SPEAKER_02 (30:34):
Wow.
Okay, so let's summarize thepill strategy.
D plus Q works, but maybe onlyif you're already carrying a
massive toxic burden ofsenescent cells.
Physicin is a highly potentweapon that essentially
detonates in your liver beforeit reaches the target.
This whole nuke them from orbitwith pill strategy is proving to
(30:55):
be highly complicated, messy,and riddled with collateral
damage issues.
Which is why some scientists arestepping back and saying, hey,
if killing these cells is thisincredibly difficult and risks
harming the tissue, maybe weshouldn't be trying to kill them
at all.
SPEAKER_00 (31:10):
It's a completely different paradigm shift.
SPEAKER_02 (31:11):
Right.
What if, instead of dropping abomb on the zombie, we just
sneak up, tape its mouth shut,and walk away, let it live, but
stop it from spitting out thetoxic sludge.
SPEAKER_00 (31:20):
Welcome to the fascinating world of
xenomorphics.
SPEAKER_02 (31:23):
Okay, I love this concept.
Let's break down xenomorphics.
If I'm trying to conceptualizethis, how does the biological
mechanism differ from whatDOCTANIB does?
SPEAKER_00 (31:31):
It's a fundamental difference in the ultimate goal.
A senolytic like Dacetanib is abiochemical assassin.
Its entire singular job is tojam the survival switchboard,
trigger apoptosis, and eradicatethe physical cell entirely.
It leaves a microcrater wherethe cell used to be.
A xenomorphic, on the otherhand, is a modulator, a diplomat
(31:52):
almost.
It does not kill the cell.
Instead, it enters the senescentcell and specifically targets
the transcription pathways thatmanufacture the SEP sludge.
SPEAKER_02 (32:00):
Like shutting down the factory assembly line.
SPEAKER_00 (32:02):
Exactly.
It blocks the internal signals,often pathways like NF kappa B
or MTOR that tell the cell toproduce interleukin 6 and all
those destructive proteases.
The cell stays alive.
It remains in its state ofarrested division.
But it is completely silenced.
SPEAKER_01 (32:17):
Muzzled.
SPEAKER_00 (32:17):
Muzzled.
You halt the bystander effect,you radically drop the local
tissue inflammation, but thephysical bulk of the cell
remains perfectly intact.
SPEAKER_02 (32:24):
Okay, I have a source here that perfectly
illustrates this in the realworld.
It's about a proprietary peptidecalled OSR1.
It was developed by a longevityskincare company called OneSkin.
And their data is superinteresting because they aren't
testing this on mice.
They applied this OSR01 peptideto actual human skin samples,
like literal ex vivo skin tissuegrown in a lab.
(32:47):
And they measured the S Azomarkers before and after.
SPEAKER_00 (32:49):
And what do the transcription markers show?
SPEAKER_02 (32:51):
The OSO1 significantly reduced the levels
of interlichin 6 and CXCO1,which we know are the major
inflammatory alarm bells in theSASP.
But here is the key it did thiswithout reducing the overall
cell viability count.
It didn't kill a single cell.
Because of that, the researchersofficially classified OSO1 as a
cinomorphic, and the physicalresults were wild.
(33:12):
By just turning off the toxicsludge, they saw reduced melanin
deposits, meaning lesshyperpigmentation, fewer age
spots, and they actually saw anincrease in epidermal thickness.
The skin structurally startedacting younger, thicker, more
resilient, purely because thechemical alarm bells were
finally turned off.
SPEAKER_00 (33:28):
It is a highly elegant, highly effective
approach, especially fordermatology.
SPEAKER_02 (33:33):
But I have to ask, and I feel like anyone listening
is thinking the exact samething.
Honestly, why wouldn't we justwant to nuke them?
I get that muzzling them worksfor a cosmetic skin cream, but
internally, it feels likefinding a live bomb in your
living room, pulling the firingwires out, and then just leaving
the casing sitting on yourcoffee table forever.
(33:53):
Why leave a muzzled zombietaking up space in your body?
Shouldn't we just sweep theminto the trash and let new cells
grow?
SPEAKER_00 (34:01):
That is a highly intuitive question, and it's the
exact debate happening ingerontology right now.
But the nuke them all approachignores the sheer physical
reality of human tissuearchitecture.
I want you to think about whathappens if you have an organ
that is heavily, heavilyburdened with senescent cells.
Let's say you are 75 years old,and 15% of the cells in a
critical area of your skin, orworse, a critical area of your
(34:23):
brain, are senescent.
SPEAKER_02 (34:24):
Okay.
15% is a lot.
SPEAKER_00 (34:26):
It's a massive amount.
Now, if you come in with ahighly potent, perfectly
absorbed synolytic and yousuccessfully nuke all of them,
you have just suddenly violentlyeradicated 15% of the physical
mass of that tissue.
Yeah.
SPEAKER_02 (34:39):
Oh wow.
You're leaving holes.
SPEAKER_00 (34:41):
You're leaving microscopic, cavernous holes
everywhere.
Now, in some tissues, this isfine.
In your liver or your blood, thesurrounding healthy stem cells
can rapidly divide, fill thegaps, and the tissue regenerates
like nothing happened.
But what about tissues that donot regenerate easily?
Or at all?
SPEAKER_01 (34:59):
Like the brain.
SPEAKER_00 (35:00):
Exactly.
Neurons in the central nervoussystem are largely postmitotic.
They do not divide to replacethemselves.
If you aggressively kill offsenescent neurons or the
senescent glial cells thatphysically support the neurons,
your body might not be able toreplace them.
You can induce rapidcatastrophic structural
degradation.
You could literally acceleratedementia by trying to cure it.
SPEAKER_01 (35:21):
Wow, that's terrifying.
SPEAKER_00 (35:22):
Right.
Or take the skin.
If you kill off 15% of thedermal fibroblasts all at once,
the skin might just physicallycollapse, losing all its
structural integrity andwrinkling dramatically.
In those highly specificsensitive environments, you
absolutely do not want to reducethe overall cell count.
You need a physical bulk of thecell to maintain the 3D
(35:43):
scaffolding of the tissue.
SPEAKER_02 (35:44):
Dude, so the zombie is still holding up the wall.
SPEAKER_00 (35:47):
Yes.
It's a load-bearing zombie.
You just need it to stopscreaming and setting the room
on fire with its SASP.
SPEAKER_01 (35:53):
Yeah.
SPEAKER_00 (35:53):
That is why xenomorphics are incredibly
important.
Sometimes muzzling the zombie isthe much safer, much more viable
biological option than totaleradication.
SPEAKER_02 (36:03):
A load-bearing zombie.
That is brilliant.
It makes total sense.
You can't just knock down thepillars of a building because
they're ugly.
Okay, so we use xenomorphics fordelicate, non-regenerating
tissues.
But what about the organs wherewe do want to wipe the board
clean, like the kidneys or theliver, where we really do want
to completely eradicate thezombies, but we don't want to
rely on these poorly absorbedplant powders, and we don't want
(36:24):
the collateral damage of broadspectrum chemo drugs.
SPEAKER_00 (36:27):
Right.
If you want to clear them outsafely, you need to abandon the
small molecule pills entirely.
SPEAKER_02 (36:32):
Exactly.
Which means we are moving pastthe pharmacy and into pure
sci-fi territory.
We need precision.
We are moving from dropping dumbbombs to sending in
precision-guided munitions.
Let's look at oisinbiotechnologies.
This is a biotech startup, andtheir approach is so radically
different from DOCTINIB orphysitin.
They aren't using chemicals topoison the cells.
(36:53):
They are using suicide genetherapy delivered via a
proteolipid vehicle.
SPEAKER_00 (36:57):
Okay, you're the expert here.
Explain the physics of aproteolipid vehicle.
How does that actually work inthe bloodstream?
It's brilliant engineering.
Think of a proteolipid vehicleas a microscopic, highly
stealthy Trojan horse.
It is essentially a tinysynthetic nanoparticle bubble
made out of fats, lipids, andspecific targeting proteins.
Inside this hollow bubble, theyhide a piece of engineered DNA.
(37:20):
This bubble is injected intoyour bloodstream.
And because its outer shell ismade of the exact same lipid
material that your cellmembranes are made of, when it
bumps into a cell, it doesn'tbounce off.
It seamlessly fuses with thecell membrane, melting into it,
and safely drops its DNA payloaddirectly inside the cell.
SPEAKER_02 (37:37):
Okay, so the Trojan horse gets inside the city
walls, it drops the syntheticDNA into the cell.
What does the DNA actually do?
Does it just start makingpoison?
SPEAKER_00 (37:46):
This is the genius part, and it solves the
collateral damage problemcompletely.
The DNA they drop inside isprogrammed to be completely
inert.
It's a dormant script.
It does absolutely nothingunless it finds itself inside a
cell that is actively expressingsenescence markers.
SPEAKER_02 (38:00):
Wait, how does it know?
SPEAKER_00 (38:01):
Because of the promoter sequence, they engineer
the DNA to only activate if itdetects a specific cellular
environment.
Usually they target the P16promoter.
The P16 gene is massivelyhyperactive in senescent cells.
It's one of the main pathwaysthey use to lock their cell
cycle.
If the Trojan horse drops theDNA into a healthy normal cell,
the healthy cell's internalmachinery looks at the DNA,
(38:24):
doesn't recognize the P16trigger, and just ignores it.
The DNA harmlessly degrades.
Nothing happens.
SPEAKER_02 (38:30):
But if it drops into a zombie cell.
SPEAKER_00 (38:31):
If it drops into a zombie cell, the cell's own
road, hyperactive P16 machineryaccidentally reads the DNA
sequence.
It triggers the script.
And the script contains theexplicit overriding instructions
for the cell to commit suicide.
It forces the cell to activateCaspace 9, which triggers
apoptosis from the inside out.
SPEAKER_02 (38:48):
That is ruthless.
It literally uses the zombie'sown corrupted machinery against
it to pull the trigger.
SPEAKER_00 (38:54):
Highly targeted, highly specific.
It completely bypasses all ofthose SCP blast fields we talked
about because it's not trying tobatter the cell from the outside
with kinase inhibitors.
It's stealthily rewriting thesoftware from the inside to
command a self-destruct.
SPEAKER_02 (39:08):
Aaron Powell And their primary target right now
is chronic kidney disease, CKD,right?
SPEAKER_00 (39:12):
Yes.
The kidneys are highly, highlysusceptible to senescent cell
accumulation as we age.
And as those cells build up, theSESP sludge drives intense
fibrosis, which is essentiallyinternal scarring.
It scars the delicate filtrationsystems of the kidney until they
fail.
Currently in modern medicine,there is very little we can do
to reverse CKD.
You just manage the declineuntil you need dialysis.
SPEAKER_02 (39:33):
But Oisin tested this in mice.
SPEAKER_00 (39:36):
They did.
And the preclinical data in miceis staggering.
By repeatedly clearing out thesenescent cells using this
precision gene therapy, theysignificantly reduced the
senescent burden in the kidneys.
They physically halted thefibrosis, the kidneys started
functioning better.
And most incredibly, when theygave this to naturally aged
mice, just regular old mice, notgenetically modified ones, this
(39:58):
technology extended their medianhealthy lifespan by over 20
percent.
SPEAKER_02 (40:02):
If you extrapolate that to a human lifespan, that's
like adding 15 or 20 healthy,vibrant years to someone's life.
Not just frail years, butfunctional years.
SPEAKER_00 (40:11):
It is an astonishing number.
Now we always have to cautionthat mice are not humans.
We've cured cancer in mice athousand times.
But the precision of thedelivery mechanism, the fact
that it avoids the livertoxicity of physicin and the
broad spectrum damage ofdocetinib is what gives
researchers so much legitimatehope.
SPEAKER_02 (40:28):
And oison isn't the only team looking at precision
targeting.
There is a massive crossoverhappening right now from the
oncology world.
Let's talk about CAR T celltherapy, because anyone who
follows cancer research knowsCAR T.
It is the ultimate personalizedmedicine.
You take a patient's own whiteblood cells out of their body,
(40:48):
you take them to a lab, youbiologically reprogram them to
recognize a specific cancermarker, and you multiply them.
You basically train a million ofyour own immune cells to act
like special forces, and thenyou put them back in the body to
hunt the cancer.
SPEAKER_00 (41:01):
That's a perfect summary of CAR T.
It absolutely revolutionized thetreatment of liquid tumors like
leukemia and lymphoma.
And now researchers have had amassive realization.
If we can train the immunesystem to hunt cancer cells, why
can't we use that exact samespecial force as training to
hunt senescence cells?
SPEAKER_02 (41:19):
Right, because the whole problem is
immunosinescence.
The immune system forgot how tofind the zombies, so we just
retrain them.
But wait, how do the immunecells know which one is the
zombie?
You can't target P16 becausethat's on the inside of the
cell.
T cells only see the outside.
SPEAKER_00 (41:34):
Exactly.
They need a surface target, abeacon.
And researchers at places likeCold Spring Harbor Laboratory
discovered a unique, highlyspecific cell surface receptor
called UPR, urokinaseplasminogen activator receptor.
It's a mouthful, but whatmatters is that UPR is broadly
heavily expressed on the outermembrane of senescent cells, but
(41:56):
it is almost entirely absent onhealthy cells.
SPEAKER_02 (41:58):
So it's literally like a glowing neon sign on the
zombie's forehead.
SPEAKER_00 (42:02):
Exactly, a neon sign that says I am senescent.
So scientists engineered CAR Tcells to exclusively hunt down
anything wearing that UPIA sign.
They took these UPR-directed CART cells and infused them into
mice.
SPEAKER_02 (42:13):
And let me guess, it worked.
SPEAKER_00 (42:14):
The immune cells acted like a highly trained HIT
squad.
They rapidly and efficientlyeradicated the senescent cells
across multiple tissues.
They reversed liver fibrosisinduced by chemicals.
And incredibly, they evenextended survival in mice that
had lung cancer.
Not because the T cells attackedthe cancer directly, but because
they cleared out the senescentcells and the surrounding tissue
(42:37):
that were creating that toxic,tumor-permissive SP environment.
They cleaned up the neighborhoodand the cancer lost its
foothold.
SPEAKER_02 (42:45):
Wow.
So if we step back and look atthe whole evolution of this
field, it's incredible.
D plus Q was like dropping awide area bomb.
It gets the job done, but youmight cause some collateral
damage to your cellularswitchboards if you don't have
enough zombies to justify it.
The seating was essentially adead missile.
The warhead was good, but itburned up in the atmosphere of
the liver before it ever reachedthe target.
But these genetic Trojan horsesand cardiotherapies, that is
(43:07):
like sending in a microscopicNavy SEAL team.
Total precision, zeroing inexactly on the target, leaving
the healthy civilian cellscompletely untouched.
SPEAKER_00 (43:17):
That is exactly the trajectory the longevity field
is taking right now, movingrapidly from repurposed blunt
chemical instruments to bespoke,hyper-precise molecular
machinery.
SPEAKER_02 (43:28):
Okay, we have covered a massive amount of
ground today.
If you are listening to this,digesting all this biology,
here's the core summary of whatyou need to take away.
Cellular senescence is real.
These zombie cells and the toxicSASP sludge they pump out are a
major fundamental mechanicaldriver of why our bodies age and
why we get sick.
(43:48):
The therapies to combat thexenolytics, to assassinate them,
the xenomorphics, to muzzle theload bearing ones are incredibly
real and showing jaw droppingpromise in the lab.
But, and this is the mostimportant takeaway, we are
currently In the messy dial upinternet phase of this science.
SPEAKER_00 (44:03):
That is such an excellent way to conceptualize
it.
Dial up internet.
SPEAKER_02 (44:06):
Right.
Like you hear the screechingmodem, it connects, it
technically works, but it dropsthe call half the time.
It's slow and it's clunky.
Avoid the hype of theover-the-counter quick fixes.
Swallowing handfuls of poorlyabsorbed plant extracts is
likely not doing what theInstagram biohacker ads tell you
it's doing.
You have to be patient.
You have to wait for theprecision medicine.
(44:28):
The Navy SEAL teams are coming,but they are still in basic
training in the phase oneclinical trials.
SPEAKER_00 (44:33):
Exactly.
Protect your health through theboring proven methods, sleep,
exercise, diet, while you waitfor the biotechnology to mature.
But while we wait for thoseclinical trials to finish, I
want to leave you, the listener,with something much deeper to
think about.
Because we spent this entirehour talking about the raw
biology of extending healthspan, the proteins in the cells,
(44:54):
but we haven't talked about thepsychology.
SPEAKER_02 (44:55):
Oh, I like where this is going.
Biology versus psychology.
SPEAKER_00 (44:58):
In our stack of sources, buried beneath all the
clinical trial data, there is afascinating report from the
Nuffield Council on Bioethics.
It explores the profound ethicaland psychological considerations
of the future of aging, and theyintroduce this brilliant concept
called psychoage.
It refers to our subjectivepsychological age, how old we
(45:19):
feel in our minds, and how thatfeeling dictates our behavior.
SPEAKER_02 (45:22):
Right, because an 80-year-old thinks very
differently about their futurethan a 20-year-old does.
SPEAKER_00 (45:27):
Exactly.
Now I want you to imagine ascenario five, maybe ten years
from now.
Let's say Oisens Gene Therapy orthe Cari T therapies actually
cross the finish line.
They get FDA approval.
They work in humans safely.
And suddenly we can reliablymedically extend human health
span by 20%.
You take a targeted treatment atage 60, and suddenly your joints
(45:48):
stop aching, your brain fogcompletely clears, your
cardiovascular system operateswith the elasticity it had when
you were 40, your biologicalclock effectively stops ticking
so loudly in your ear.
SPEAKER_02 (45:59):
I mean, that sounds like the ultimate dream.
Sign me up.
SPEAKER_00 (46:01):
It does sound like a dream.
But what actually happens tohuman psychology when that
biological clock stops?
Think about it.
So much of human ambition, ourintense drive to create, to
build companies, to paintmasterpieces, to start families,
to achieve our goals, it issubconsciously heavily driven by
the ticking of that clock.
We know deeply that our time islimited.
(46:23):
Our bodies remind us every day,so we act with urgency.
SPEAKER_02 (46:27):
Art is long, life is short.
The deadline is what forces youto do the work.
SPEAKER_00 (46:31):
Exactly.
The deadline forces the action.
So here's the philosophicalquestion.
If you know with relativemedical certainty that you have
decades and decades of healthy,vibrant, pain-free life
stretching out ahead of you,does your psychological drive
fundamentally change?
Does the urgency of lifedisappear?
Do we become a society ofprocrastinators, becoming
(46:51):
complacent because there'salways tomorrow or next decade
to write that book or changecareers?
SPEAKER_02 (46:56):
That's a dark thought, like we just lose our
fire.
SPEAKER_00 (46:58):
Or conversely, does removing the subconscious terror
of physical decline and deathfinally free you?
Does taking away the anxiety ofa failing body allow you to
truly live, to take massiverisks, to learn a fifth
language, to start overcompletely at age 70 without
fear?
Does it unlock a completely newphase of human potential that we
haven't even evolved tounderstand yet?
SPEAKER_02 (47:19):
Wow.
If the biological scaffoldingholds up and suddenly we have a
clear, realistic path to ahundred or a hundred and twenty
healthy functional years, whatdo we actually do all that time?
Who do we become?
That is something for you tochew on until next time.
Right now, inside your body, a microscopic
rebellion is taking place.
I'm totally serious.
Like, as you're listening tothis right now, certain cells in
your tissues have sufferedmassive DNA damage.
But instead of doing thehonorable thing and just, you
know, dying to make room forhealthy cells, they've gone
rogue.
SPEAKER_00 (00:19):
They really have.
SPEAKER_02 (00:20):
Right.
They've raised these biologicalshields, locked themselves deep
into your tissue, and juststarted actively spewing toxic
sludge at their neighbors.
SPEAKER_00 (00:28):
Aaron Powell It is a it's a genuinely terrifying
biological reality when youphrase it exactly like that.
But honestly, it's highlyaccurate.
SPEAKER_02 (00:36):
I know, right?
You've probably seen theheadlines floating around.
They're literally everywhere.
Things like uh zombie cells inyour organs or some billionaire
tech bro spending millions tocure aging and live to be 150.
SPEAKER_00 (00:48):
Aaron Powell Oh, the tech bro headlines are endless
right now.
SPEAKER_02 (00:50):
Endless.
And it sounds like pure sciencefiction, like the plot of a bad
zombie movie where theapocalypse just starts in a
petri dish.
But today we are cuttingstraight through all of that
internet hype.
We're going to talk about whatis actually happening in your
biology right this second.
And trust me, the actual scienceis way weirder and way more
fascinating than the clickbaitmakes it sound.
SPEAKER_00 (01:11):
Trevor Burrus, Jr.
It really is.
The reality of the biology hereis just it's so much more
complex than, you know, takethis magical biohacker pill and
live forever.
SPEAKER_01 (01:19):
Yeah.
SPEAKER_00 (01:20):
Aging isn't just this abstract concept of time
passing.
You know, it's not just thecalendar flipping over and your
body suddenly deciding to ache.
It's driven by very distinct,physical, measurable biological
mechanisms.
And today, we are zeroing in onone of the absolute biggest
culprits, a phenomenon calledcellular senescence.
SPEAKER_02 (01:39):
Aaron Ross Powell Exactly.
And that is the mission for thisdeep dive.
We have a massive stack ofsources to go through with you
today.
We're talking human clinicaltrials, real human data, not
just mice out of Georgia, thecountry, not the state and the
Mayo Clinic.
SPEAKER_00 (01:52):
Aaron Powell The human data is where things get
really interesting.
SPEAKER_02 (01:55):
Totally.
We've got biotech startup pressreleases, deeply dense
physiological reviews, all ofit.
And we are going to figure outwhat these so-called zombie
cells actually are, what thesedrugs called synolytics actually
do, and most importantly,whether this science is actually
ready for you to use, or ifyou're just, you know, flushing
(02:16):
your money down the toilet,buying expensive powders online.
SPEAKER_00 (02:19):
Which, spoiler alert, a massive amount of
people are currently doing.
But I think before we even touchon the drugs that supposedly
clear these things out, wereally have to ground this in
the biology.
We need to unpack what a zombiecell actually is.
Because your body doesn't justspontaneously generate monsters
to ruin your life.
There is a deeply ingrainedevolutionary reason they exist.
(02:40):
Aaron Powell Right.
SPEAKER_02 (02:41):
So let's get into it.
Because I hear a term likecellular senescence, and my
brain just defaults to likecells getting old and tired and
eating a nap.
SPEAKER_00 (02:49):
Right, the fatigue theory.
SPEAKER_02 (02:50):
Yeah, like they just run out of gas.
But it's way more aggressivethan that.
It's an active state.
SPEAKER_00 (02:55):
It is an incredibly active state.
It's not passive decay at all.
So let's step back and look atthe basics of how your body
maintains itself.
In normal, healthy tissue, yourcells divide.
They replicate to replace old,damaged, or dead tissue.
You get a cut, your skin cellsdivide to heal it.
But, and this was a massiveparadigm shift in biology, they
(03:18):
cannot do this forever.
SPEAKER_02 (03:19):
Wait, really?
I thought that was the wholepoint of cells.
They just keep copyingthemselves.
SPEAKER_00 (03:22):
For a long time, scientists thought that too.
Back in the early 20th century,there was this famous, though
highly flawed experiment byAlexis Carroll, where he claimed
to keep chicken heart cellsdividing in a lab for decades.
SPEAKER_01 (03:36):
Oh, wow.
SPEAKER_00 (03:36):
Yeah, people thought cells were essentially immortal.
But then in 1961, theseresearchers, Leonard Hayflick
and Paul Moorhead, completelyshattered that myth.
They discovered that human cellscultured in a lab have a strict
hardwired limit on how manytimes they can divide.
It's called the Hayflick limit,usually around 40 to 60
divisions for a human cell.
SPEAKER_02 (03:55):
Aaron Powell So they literally just hit a wall, like
a biological kill screen in avideo game.
SPEAKER_00 (03:59):
Aaron Ross Powell Exactly.
And the mechanism behind thiswall is fascinating.
It largely comes down totelomeres.
SPEAKER_02 (04:05):
Aaron Powell Oh man.
Okay.
I know exactly where this isgoing.
Every biology textbook I everread uses that same awful
metaphor for telomeres.
The little plastic caps at theend of your shoelaces.
SPEAKER_00 (04:16):
Trevor Burrus, Jr.
It's everywhere.
SPEAKER_02 (04:17):
Trevor Burrus, I always hated that.
It never made sense to me.
What happens when the cap fallsoff, the DNA shoelace just frays
into strings?
SPEAKER_00 (04:24):
Aaron Powell I agree.
The shoelace analogy isincredibly overused and honestly
functionally misleading.
A much better way to think abouta telomere is like a prepaid
biological debit card for celldivision.
SPEAKER_02 (04:37):
Trevor Burrus, oh I like that.
Okay, so every time the celldivides, it swipes the card.
SPEAKER_00 (04:41):
Aaron Ross Powell Exactly.
Every time a cell replicates itsDNA to divide, the machinery
that copies the DNA can't quitereach the very, very end of the
strand.
So a tiny piece of the telomere,which is just a repeating
sequence of junk DNA thatdoesn't code for anything
important, is left off.
It's the transaction fee.
SPEAKER_02 (04:57):
Right.
SPEAKER_00 (04:58):
You swipe the card, you lose a little bit of the
balance, the telomere getsphysically shorter.
SPEAKER_02 (05:01):
Okay, I'm tracking.
So you keep dividing, you keepswiping the card, and eventually
the balance hits zero, carddecline.
SPEAKER_00 (05:08):
Card decline.
The telomere becomes criticallyshort.
And when that happens, thecell's internal sensors freak
out.
They recognize that if theydivide again, they won't be
cutting into junk DNA.
They'll be cutting intoessential crucial genes.
SPEAKER_01 (05:21):
Oh, it makes sense.
SPEAKER_00 (05:22):
The cell realizes I am severely damaged.
If I replicate now with brokenDNA, I might mutate.
I might become a cancer cell.
SPEAKER_02 (05:30):
Ah.
So the climate isn't a flaw,it's a safety mechanism.
It's slamming the brakes beforethe car goes off the cliff.
SPEAKER_00 (05:36):
Precisely.
It's an incredibly elegant tumorsuppressor mechanism.
And usually when a cell reachesthat state or if it experiences
severe acute stress like amassive dose of radiation or
intense oxidative stress orcertain viral infections, it is
supposed to do the biologicallynoble thing.
It triggers a programmedself-destruct sequence.
SPEAKER_02 (05:55):
Aoptosis.
SPEAKER_00 (05:56):
Yes, apoptosis.
The cell neatly and quietlypackages its internal components
into these little lipid vesiclesand it sends out a signal to the
immune system.
Macrophages, which areessentially your body's garbage
trucks, swoop in and eat thevesicles.
SPEAKER_02 (06:12):
Just cleans it right up.
SPEAKER_00 (06:14):
It's clean, it doesn't cause inflammation, and
the surrounding tissue iscompletely unharmed.
That is how a healthy body staysyoung and functional.
SPEAKER_02 (06:21):
But and I'm guessing this is the crux of the whole
deep dive.
Sometimes they don't do thenoble thing.
SPEAKER_00 (06:26):
Sometimes they absolutely refuse to die.
SPEAKER_02 (06:28):
They just say no.
They override the self-destruct.
SPEAKER_00 (06:31):
They override it completely.
They arrest their cell cycle,meaning they permanently,
irreversibly stop dividing, butthey stay alive, they dig in,
they turn on these highlyspecific, highly robust
anti-apoptotic pathways.
Basically, they raise internalblast shields to resist their
own death signals.
SPEAKER_02 (06:48):
Dude, that is deeply creepy.
SPEAKER_00 (06:50):
And that that is what a senescent cell is.
That is your zombie.
It's not dead, it refuses todie, but it is entirely stripped
of its normal, healthy function.
SPEAKER_02 (06:58):
It just sits there taking up space, refusing to
clock out.
But wait, if they're justsitting there, not dividing, why
are they such a massive problem?
Like if I have a zombie cellparked in my bicep or my liver
and it's not turning intocancer, who cares?
Why is it driving systemicaging?
SPEAKER_00 (07:14):
Aaron Powell Because they aren't just sitting there
quietly taking up space.
This is the biggestmisconception about senescence.
They are highly, franticallymetabolically active and they
are screaming.
Screaming.
Chemically screaming.
And this introduces a piece ofjargon that is absolutely
central to everything we'retalking about today.
It's an acronym, S-A-S P.
(07:35):
It stands for the SenescenceAssociated Secretary Phenotype.
SPEAKER_02 (07:38):
S-A-S-P.
Honestly, looking at the papers,phenotype feels way too
clinical.
I'm just going to call it ToxicZombie Sludge because when you
read what it actually does tothe surrounding tissue, it
sounds like radioactive sludge.
SPEAKER_00 (07:49):
You know, toxic zombie sludge is scientifically
crude, but it is functionallybrilliant because it really
captures the destructive natureof it.
But to give you the precisebiological breakdown, this
sludge is a highly complex,continuously secreted cocktail
of proteins.
SPEAKER_02 (08:06):
Okay, what kind of proteins?
SPEAKER_00 (08:07):
We are talking about pro-inflammatory cytokines,
specifically things likeinterleukin-6 or IL6 and
interleukin 8.
We're talking about chemokines,which summon immune cells to the
area.
We're talking about heavy-dutygrowth factors.
And worst of all, proteas.
SPEAKER_02 (08:23):
Wait, remind me what a protease does.
It breaks things down, right?
SPEAKER_00 (08:26):
Yes.
Proteases are enzymes thatliterally chew up proteins.
Matrix metal proteinasesspecifically degrade the
extracellular matrix, thestructural scaffolding that
holds your tissues together.
SPEAKER_02 (08:38):
So they're actively destroying the neighborhood.
SPEAKER_00 (08:41):
They are.
SPEAKER_02 (08:41):
It's like a bad tenant.
They park on the lawn, theyrefuse to leave, and then they
just start dumping battery acidon the grass, throwing trash
everywhere, and blasting loudmusic all night to keep everyone
else awake.
SPEAKER_00 (08:52):
That is a phenomenal analogy.
The tissue degradation is veryreal, but it gets even worse
than the battery acid on thelawn.
Because of the specific natureof this SCSP sludge, it doesn't
just degrade the scaffolding.
It actually infects theneighboring healthy cells.
Researchers call it thebystander effect.
SPEAKER_02 (09:12):
Hold on.
You're saying the sludge fromthe zombie hits a perfectly
healthy cell next door and doeswhat?
Does the healthy cell die?
SPEAKER_00 (09:19):
No, it doesn't die.
The inflammatory signals,especially the cytokines and the
reactive oxygen species in theSSP, cause immense stress to the
healthy neighbor.
And that stress forces thehealthy cell to also trigger its
blast shields, lock its cellcycle, and become senescent.
SPEAKER_02 (09:36):
No way.
It actually turns them intozombies too.
SPEAKER_00 (09:39):
It does.
SPEAKER_02 (09:39):
It's a literal zombie bite.
One gets infected, turns, andthen immediately starts biting
the neighbors.
That is insane.
It's an exponential infectionmodel.
SPEAKER_00 (09:47):
It is exactly an infection model, just driven by
chemistry rather than a virus.
And as this chain reactionspreads through a tissue, it
drives a massive systemicproblem that researchers have
termed inflammaging.
SPEAKER_02 (09:59):
Inflammaging.
Inflammation plus aging.
SPEAKER_00 (10:01):
Exactly.
It's this chronic, low-grade,simmering systemic inflammation
that creeps up on all of us aswe get into our 40s, 50s, and
beyond.
If you look at the sources, themedical consensus is crystal
clear.
This inflammaging, driven at itscore by the SAP sludge, is
fundamentally linked to almostevery major disease of aging.
SPEAKER_02 (10:23):
Like what specifically?
SPEAKER_00 (10:24):
Cardiovascular disease, atherosclerosis, type 2
diabetes, neurodegeneration likeAlzheimer's and Parkinson's,
osteoarthritis, and ironicallylate-life cancers.
SPEAKER_02 (10:35):
Wait, ironically, because you just said senescence
evolved to stop cancer.
SPEAKER_00 (10:38):
But it does initially.
But remember that SASP cocktail.
It's full of growth factors andenzymes that chew up the tissue
matrix.
If a legitimate cancer cell doesmanage to form nearby, that
degraded tissue and those growthfactors provide the perfect
fertile soil for a tumor torapidly grow and metastasize.
It's a tragic paradox.
SPEAKER_02 (10:56):
Okay, I have to push back here.
Because my brain is spinning.
SPEAKER_00 (10:58):
Go for it.
SPEAKER_02 (10:59):
If these zombie cells are so incredibly toxic,
if they literally secrete asludge that melts our tissues,
infects other cells, and causesour bodies to break down and
die, why did evolution let themexist?
Why didn't our bodies justevolve to instantly nuke any
cell that turns senescent?
It seems like a massive glaringdesign flaw in the human
blueprint.
SPEAKER_00 (11:20):
That is the million-dollar question in
gerontology.
And the answer lies in a conceptcalled antagonistic pleiotropy.
SPEAKER_01 (11:27):
Okay, that is a mouthful.
Unpack antagonistic pleiotropyfor me.
SPEAKER_00 (11:31):
It sounds intimidating, but the concept is
simple.
It refers to a biologicalfeature or a gene that is highly
beneficial when you are youngand trying to survive, but
becomes actively detrimentalwhen you are old.
You have to remember howevolution works.
Right.
Evolution only really caresabout one thing: getting you to
reproductive age and keeping youalive long enough to raise your
offspring.
What happens to your joints oryour brain at age 70 or 80,
(11:54):
evolution doesn't care.
There's no evolutionary pressureto fix problems that only kill
you after you've passed on yourgenes.
SPEAKER_02 (12:01):
So you're saying the zombie sludge, the SAP, is
actually good for you whenyou're young?
SPEAKER_00 (12:06):
It is absolutely crucial for your survival.
Here's the twist that blowspeople's minds.
When you're young, say you're ahealthy 20-year-old and you get
a severe cut or a muscle injury,cells in that specific area
temporarily become senescent.
They rapidly pump out that SAPsludge.
But in a young, healthy body,that acute burst of inflammation
(12:26):
isn't a chronic burn.
It's a massive glaring signalflare.
SPEAKER_02 (12:30):
Like calling 911.
SPEAKER_00 (12:31):
Exactly.
Tells your immune system, hey,massive damage here.
Send the macrophages, send therepair stem cells immediately.
The SAP actually orchestratesthe wound healing process.
It promotes tissue regeneration.
Oh wow.
And even crazier, duringembryonic development, when you
are literally a fetus growing inthe womb, transient senescent
cells use their SAP to helpsculpt the growing tissues.
(12:54):
They create the temporaryscaffolding, signal the growth,
and then gracefully clear out.
SPEAKER_02 (12:58):
Wait, wait, wait.
We use zombie sludge to grow asembryos, that's how we develop.
SPEAKER_00 (13:02):
We do.
Without senescence, you wouldn'tdevelop properly.
The mechanism is a masterpieceof biology.
The problem isn't that senescentcells exist.
The system works perfectly whenwe are young.
The cell gets damaged, turnssenescent, shoots up this view
flare, stops itself frombecoming cancer, and then the
immune system, the garbagetrucks, sees the flare, swoops
in, and eats the senescent cell.
(13:24):
Tissue healed, danger averted.
SPEAKER_02 (13:26):
Okay, so the system is a closed loop.
What breaks?
Why do they accumulate whenwe're older?
SPEAKER_00 (13:30):
What breaks is the immune system itself.
As we age, our immune systemundergoes a parallel process
called immunosinescence.
The garbage trucks get tired,the macrophages become less
efficient at recognizing the SACflares, the natural killer cells
get sluggish.
SPEAKER_02 (13:45):
Oh, so the dispatcher is ignoring the 911
calls.
SPEAKER_00 (13:49):
Precisely.
The senescent cells are stillforming because your cells are
still dividing, getting stressedby toxins, poor diet, UV
radiation, simple time, and theyare still shooting at their SAC
flares.
But the immune system just stopsshowing up to clear them out.
SPEAKER_02 (14:01):
So they just sit there, multiplying.
SPEAKER_00 (14:02):
They accumulate.
And because of that bystandereffect we talked about, the
longer they sit there, the morehealthy neighbors they infect.
The inflammation transitionsfrom being a helpful, acute
alarm bell into a chronic,low-level, relentless burn.
And that chronic burn is whatslowly destroys your tissue
architecture over decades.
SPEAKER_02 (14:22):
Wow.
Okay.
That makes perfect sense.
It's a failure of clearance, nota failure of design.
So the immune system is slackingoff, the zombies are biting the
neighbors, the tissue is fillingup with sludge, which perfectly
leads us into the logical nextstep.
If our bodies can't naturallyclear them out anymore, how do
we intervene?
How do we build an artificialgarbage truck to flush them out?
SPEAKER_00 (14:43):
And this brings us to the advent of senolytics.
The drugs designed to do exactlywhat our immune system forgot
how to do.
SPEAKER_02 (14:49):
Right.
Let's talk about killing them.
Because if you want to kill azombie, you have to know how
it's surviving.
You mentioned earlier they haveblast shields.
SPEAKER_00 (14:56):
Yes.
To understand a senalytic drug,you have to understand the S
keeps senescent cellanti-apoptotic pathway.
SPEAKER_01 (15:04):
The blast shields.
SPEAKER_00 (15:05):
Exactly.
When researchers first startedtrying to kill these cells, they
realized it was incrediblydifficult.
The cells were stubborn.
So they did these massivebiointraumatic screens.
They looked at the transcriptum,meaning they looked at exactly
which genes were turned on andwhich were turned off in a
senescent cell compared to ahealthy cell.
Right.
And they found that senescentcells heavily, desperately rely
(15:28):
on certain survival networks,specifically families of
proteins like the BCL2 family orcertain tyrosine kinases.
SPEAKER_02 (15:35):
Okay, break those down for me.
What is a tyrosine kinase doingin this context?
SPEAKER_00 (15:39):
Think of a tyrosine kinase, like a highly specific
switchboard operator inside thecell.
Its job is to take signals,often survival signals, and pass
them down the chain to tell thecell, keep the blast shields up,
do not trigger apoptosis, stayalive.
Senescent cells have theseswitchboards jammed in the on
position.
They are completely dependent onthese specific pathways to
(16:01):
survive the massive internalstress of being a zombie.
SPEAKER_02 (16:04):
So they're basically on life support.
SPEAKER_00 (16:05):
Exactly.
They are teetering on the edgeof self-destruction, only kept
alive by these hyperactive SDFCshields.
So the theory was born.
What if we use a drug to justtemporarily jam the switchboard?
Turn the shield off for just aminute.
A healthy cell wouldn't carebecause a healthy cell isn't
under massive stress, it doesn'tneed emergency shields to
(16:27):
survive.
SPEAKER_02 (16:28):
But a senescent cell-If you pull the plug on its
life support, even for a second,the whole thing crashes and it
dies?
SPEAKER_00 (16:34):
Yes, it's pushed over the edge into apoptosis, it
finally dies.
Drugs that do this are calledsenolytics.
They selectively induce death insenescent cells while leaving
healthy cells entirely alone.
And the fascinating thing is,when researchers figured this
out, they didn't have to inventa completely new drug from
scratch.
The very first wave ofsynolytics were compounds we
(16:54):
already had in the pharmacy inthe grocery store.
SPEAKER_02 (16:56):
Yes.
Okay, let's talk about the mostfamous combo in this space,
because this is where the humandata gets wild.
D plus Q.
SPEAKER_00 (17:03):
Dacidamib and Quircetin.
SPEAKER_02 (17:04):
Right.
So D is docetamib, which, if I'mreading this right, is an
intense FDA-approved leukemiadrug.
It's literal chemotherapy.
And Q is quercetin, which is anatural flavonoid plant
compound.
You can buy it in a plasticbottle at the vitamin Ile.
It's in apples, onions, capers.
How did they end up pairing aheavy-duty cancer drug with an
(17:27):
apple extract?
SPEAKER_00 (17:28):
It comes back to those switchboards.
Docitative is a broad spectrumtyrosine kinase inhibitor.
It's very good at jammingcertain survival signals,
specifically theefferin-dependent pathways, but
it doesn't hit all of them.
Quircetin, on the other hand,inhibits completely different
survival pathways like PI3K andcertain serpents.
Neither one of them is strongenough to clear out all types of
senescent cells on their own.
SPEAKER_02 (17:49):
But together cover each other's blind spots.
SPEAKER_00 (17:51):
Precisely.
Together, they hit multiple SCOAshields simultaneously across
different tissue types.
It was the ultimate one-twopunch.
And the preclinical data in micewas absurd.
It extended their lifespan,rejuvenated their cardiovascular
systems, but mice are mice.
The real question was whathappens in a human?
SPEAKER_02 (18:07):
Which brings us to the Republic of Georgia trial.
This was a 2019 clinical trial,and reading the methodology of
this study honestly blew mymind.
So they took 64 men, middle agedto older, the average age was
around 53, and they gave themthis D plus Q combo.
But here is the part that Ifound so crazy the dosing
(18:27):
schedule.
They didn't put them on a dailypill.
They gave them 50 milligrams ofdecetinib and 500 milligrams of
quercetin once a day for justfive days, and then they stopped
completely.
SPEAKER_00 (18:40):
This is a crucial concept in senotherapeutics.
It's called a hit and run dosingstrategy.
Think about the biology.
Senescent cells do not divide,they can't multiply.
So if you go in with a senolyticstrike team and clear out, say
30% of the zombies over fivedays those cells are gone, it'll
take weeks, maybe months, forthe natural stresses of life to
accumulate a new batch ofsenescent cells.
SPEAKER_02 (19:01):
So you don't need to suppress the pathway constantly.
SPEAKER_00 (19:05):
Exactly.
And that is incredibly fortunatebecause as you mentioned,
dustatinib is a chemotherapydrug.
If you take it every day formonths, it has massive side
effects, immunosuppression,bleeding, severe fatigue.
But a five-day pulse, the sideeffects are minimal.
SPEAKER_02 (19:21):
Okay, so five days of pills, then they waited 21
days, three full weeks.
The drugs are completelymetabolized, long gone from
their bloodstream, and then theytested them.
They had these guys do a stairascending test.
And this isn't just can you walkupstairs?
They are hooking them up toblood pressure monitors, timing
their endurance, seeing howtheir cardiovascular system
(19:42):
handles the acute stress ofclimbing four flights, and the
results The results were aprofound proof of concept.
Weeks after the drugs were gone,these 53-year-old men had
significantly improved physicalendurance.
Their times were faster.
But the craziest part was theblood pressure.
Their systolic blood pressuredropped, and their vitals
stabilized way faster after theexercise.
(20:02):
I need you to explain the howhere.
How does clearing out somerandom zombie cells three weeks
ago suddenly make a guy's bloodvessels work better today?
SPEAKER_00 (20:10):
It's all mechanical, driven by the removal of the
SASP.
Remember when we talked aboutthe proteases and the toxic
sludge, the enzymes that chew upthe extracellular matrix?
SPEAKER_02 (20:20):
Yeah, the ones destroying the neighborhood
scaffolding.
SPEAKER_00 (20:22):
Right.
Your blood vessels rely on aprotein called elastin to remain
stretchy and flexible.
That flexibility is whatregulates your blood pressure.
When your cardiovascular systemis loaded with senescent cells,
the constant bath of SAPproteases literally chews up
that elastin.
The blood vessels become stiff.
Stiff vessels mean high bloodpressure.
SPEAKER_01 (20:43):
Oh that is crazy.
SPEAKER_00 (20:45):
When the D plus Q pulsed through their system, it
triggered apoptosis and afraction of those senescent
cells in the endothelial liningof the vessels.
The cells died, the macrophagescleared the debris, and suddenly
the SSA sludge vanished.
The proteases stopped chewing upthe elastin.
The vessels rapidly regainedtheir natural elasticity, which
mechanically lowered the bloodpressure.
And on top of that, without thesystemic inflammation,
(21:07):
practically everyone in theactive D plus Q group reported
feeling a literal lightness inthe joints the very next day.
SPEAKER_02 (21:13):
Dude, that is unbelievable.
So it's not a stimulant, it'snot masting a symptom, it's
structurally repairing thetissue by removing the toxic
variable.
If I'm a listener right now, myimmediate thought is: okay,
where do I get a prescriptionfor DAS at nib?
I want my joints to feel lighttomorrow.
SPEAKER_00 (21:30):
And that is exactly where I need to step in and
throw a massive bucket of coldwater on the hype.
Because while the Georgian trialis incredibly exciting, science
is never just one study.
One study is an anomaly,multiple studies are data.
We have to look at the MayoClinic trial that was also in
our sources because this addssome very dry, very necessary
clinical reality to theconversation.
SPEAKER_02 (21:51):
All right, hit me with the reality check.
SPEAKER_00 (21:53):
The Mayo Clinic conducted a phase two,
randomized placebo controlledtrial using the exact same D
plus Q.
Combination, the same protocol.
But this time they tested it on60 healthy postmenopausal women.
SPEAKER_02 (22:06):
Why specifically postmenopausal?
SPEAKER_00 (22:08):
Because of estrogen.
When women go through menopause,estrogen levels plummet.
Estrogen is heavily involved inregulating bone metabolism.
Without it, bone resorption, thebreaking down of bone,
accelerates, which is whyosteoporosis is such a massive
risk.
And cellular senescence in thebone marrow is a huge driver of
this.
The senescent cells secrete SESPthat hyperactivates osteoclasts,
(22:31):
the cells that eat bone.
So the Mayo Clinic wanted to seeif we give these women D plus Q,
can we kill the senescent cellsand improve their bone formation
markers?
SPEAKER_02 (22:42):
Okay, that makes total sense.
So they tracked their bonemarkers.
What happened?
Did it work?
SPEAKER_00 (22:46):
Well, yes and no.
It did have a beneficial effecton bone formation markers like
P1MP, it reduced boneresorption, it did biologically
what it was supposed to do.
But, and this is a massive,highly critical, but when they
dug into the data, they found itonly benefited the women who
already had a significantly highbaseline burden of senescent
cells.
SPEAKER_02 (23:04):
Wait, really?
Only the ones with a highburden.
SPEAKER_00 (23:06):
Yes.
They measured the senescenceburden before the trial started.
If a woman had a relatively lownumber of senescent cells to
begin with, if her biologicalage was doing okay, the D plus Q
did virtually nothing for herbone health.
The markers barely moved.
SPEAKER_02 (23:23):
Oh, so it's not a prophylactic.
It's not a magic anti-agingvitamin that just buffs your
stats.
SPEAKER_00 (23:29):
Not at all.
Dr.
Sundit Kosla, who is a brilliantresearcher and the senior author
from the Mayo Clinic on this,gave a very stark warning about
this exact dynamic.
He pointed out that there aretens of thousands of people out
there right now reading theheadlines, buying commercial
coracetin online, and taking itevery single day as an
anti-aging supplement.
But his point is foundational.
(23:50):
If you don't actually have ahigh burden of senescent cells
in your tissues, taking asenolytic won't do anything for
you.
SPEAKER_02 (23:56):
It's like taking a highly potent weed killer,
walking out to a perfectlymanicured lawn that doesn't have
a single dandelion on it, andjust spraying chemicals
everywhere.
You're not making the grasshealthier, you're just pouring
poison on a healthy lawn for noreason.
SPEAKER_00 (24:08):
That is the perfect analogy.
If there are no zombies to kill,the zombie-killing drug does not
make you younger.
And it's not just useless, itcarries risk.
Taking high doses of kinaseinhibitors, even natural ones
when you don't need them, isjust asking for off-target side
effects.
You're jamming cellularswitchboards that might actually
need to be on.
SPEAKER_02 (24:28):
Right, because healthy cells need those
pathways too.
SPEAKER_00 (24:31):
Exactly.
Koslan noted that people withaccelerated aging conditions,
like cancer survivors who wentthrough heavy chemotherapy,
chemo massively induces cellularsenescence, which is why chemo
survivors often suffer fromearly frailty and heart issues.
Or people with severe obesity orprogeroid syndromes, those
people have massive zombieburdens.
(24:52):
They might benefit immenselyfrom D plus Q.
But a relatively healthy40-year-old taking kerosetin
every morning hoping to live to120, you're probably just making
incredibly expensive urine.
SPEAKER_02 (25:03):
Okay, if you're listening to this and looking at
that bottle of supplements onyour kitchen counter, you might
be feeling a little betrayedright now, which makes this the
perfect time to talk about theabsolute king of the supplement
hype cycle right now, physicin.
SPEAKER_00 (25:15):
Yes.
We absolutely have to talk aboutphysiotin.
SPEAKER_02 (25:18):
Because if you go online to any biohacking forum
or listen to certainoptimization gurus, physicin is
the golden child.
It's another natural flavonoid,very similar to quercetin.
You find it naturally instrawberries, apples,
persimmons.
And the hype didn't come out ofnowhere.
In petri dishes, invitrofeasitin looked like an
absolute miracle.
It looked like a highly potentsynolytic, maybe even better and
(25:40):
safer than the D plus Q combo,and you don't need an oncologist
to prescribe it to you, sopeople are buying it in bulk.
But our stack of sourcesincludes a very recent, highly
rigorous clinical trial from theStedman Philippon Research
Institute in Colorado, and thistrial is a total wake-up call.
SPEAKER_00 (25:57):
It really is.
This was a phase one and tworandomized, double-blind,
placebo-controlled trial.
That is the absolute goldstandard of clinical research.
No bias, no guessing.
SPEAKER_02 (26:08):
Exactly.
Let's break down the setup.
They took 74 subjects, rangingfrom 40 to 80 years old, who all
had radiographically confirmedosteoarthritis in their knees.
We are talking severe,bone-on-bone, painful joint
degradation.
And the biological rationalehere is rock solid.
We know from extensiveliterature that osteoarthritic
(26:28):
joints are basically ground zerofor senescence.
The cartilage is absolutelypacked with senescent
chondrocytes, and the SSPinflammation is what drives the
pain and the cartilage isdestruction.
SPEAKER_00 (26:38):
So the setup is pristine.
You have a localized, highlyburdened target area.
SPEAKER_02 (26:43):
Right.
So they split the group, halfget a placebo, half get oral
physicin.
And the dosing protocol wasintense.
They gave them 20 milligrams perkilogram of body weight.
So for an average guy, that'slike taking a massive fistful of
capsules.
They did it for two consecutivedays, then 28 days off.
The hit and run strategy again,they did three full cycles of
this, and then they trackedthese patients for an entire
year.
And they didn't just ask, how doyour knees feel?
(27:05):
They did deep metric tracking.
They used MRI T2 mapping.
SPEAKER_00 (27:09):
Which, for context, is an advanced imaging technique
that allows you to see themicroscopic water content and
collagen integrity inside thecartilage.
It shows you the actualstructural health of the tissue,
not just the gross bone gap.
SPEAKER_02 (27:22):
Thank you.
Yes.
They did T2 mapping, they didthe WLMAC pain and stiffness
surveys, they did 40-meter fastwalk tests, timed up and go
tests.
They measured literally everyfunctional metric you can think
of.
SPEAKER_00 (27:34):
Aaron Powell And what did the year of data
reveal?
SPEAKER_02 (27:36):
Total, absolute failure.
SPEAKER_00 (27:37):
Aaron Powell Completely null results across
the board.
SPEAKER_02 (27:40):
Aaron Powell I was reading the graphs and the
source data, and it's almostcomical in a dark way.
The trend lines for the Fissetingroup and the placebo group are
practically glued together.
No significant differences inthe MRI cartilage scans.
The cartilage kept degrading atthe same rate.
No difference in pain reduction.
No difference in physicalfunction, knee strength, or gate
speed.
(28:00):
Honestly, reading it made me abit angry.
Because people are dropping realcash on this stuff, they are
popping these massive doses ofpills, and it's doing literally
nothing in a human body.
SPEAKER_00 (28:10):
It is deeply frustrating, but it is a harsh,
necessary lesson intranslational medicine.
And the lesson is this.
Just because a moleculesuccessfully assassinates a
zombie cell in a perfectlycontrolled artificial
water-based environment like apetri dish, does not mean that
swallowing a plastic capsule ofit will fix your biological
hardware.
SPEAKER_02 (28:28):
Okay, so unpack the why here.
If fecetin is a proven sanolyticin the lab, why did it fail so
spectacularly in the humans?
Did they not use a high enoughdose?
SPEAKER_00 (28:37):
It's not a dosage issue.
It fundamentally comes down topharmacokinetics, specifically a
concept called bioavailability.
Ficetin, in its pure, naturalmolecular form, is highly,
highly hydrophobic.
It actively repels water.
SPEAKER_02 (28:51):
Like trying to mix olive oil into a glass of tap
water, it just clumps up andseparates.
SPEAKER_00 (28:55):
Exactly.
Now think about your digestivesystem.
Your stomach acid, the mucosallining of your intestines, your
bloodstream, your body, isoverwhelmingly water.
When you swallow pureficitinpowder, it hits that watery
environment and struggles todissolve.
And even if a little bit getsabsorbed to the gut lining, it
immediately hits the liver.
(29:15):
The liver's entire job is tofilter out foreign, poorly
soluble compounds.
It undergoes what's calledmassive first-pass metabolism.
The liver shreds the cissetinand excretes it before it ever
gets a chance to circulate inthe blood, let alone penetrate
the dense vascular tissue of thesynovial fluid inside a knee
joint.
SPEAKER_02 (29:33):
So the physicin wasn't failing to kill the
zombie cells, it just never evenreached the battlefield.
It was intercepted at theborder.
SPEAKER_00 (29:39):
That is the most medically probable explanation.
Swallowing pure fysitin is liketrying to wash your car with a
sponge wrapped in duct tape.
The soap is in there, but itcan't get out to do the work.
And this highlights a massive,foundational lesson for anyone
interested in longevity science.
Delivery mechanisms matter justas much, if not more, than the
(30:00):
drug itself.
You could have the greatest,most lethal biochemical warhead
in the world, but if you do nothave a missile guidance system
that can successfully deliver itto the target tissue, the
warhead is completely useless.
SPEAKER_02 (30:12):
Man, that is a brutal reality check.
And the researchers in the studywere pretty clear about this,
right?
They didn't say the concept ofsynolytics is dead.
They just said this specificoral formulation of physicin is
a dead end.
SPEAKER_00 (30:23):
Correct.
They are currently looking intoliposomal physicin, or injecting
it directly into the joint.
But the oral supplement you buyonline, the data says it's
functionally inert for yourknees.
SPEAKER_02 (30:34):
Wow.
Okay, so let's summarize thepill strategy.
D plus Q works, but maybe onlyif you're already carrying a
massive toxic burden ofsenescent cells.
Physicin is a highly potentweapon that essentially
detonates in your liver beforeit reaches the target.
This whole nuke them from orbitwith pill strategy is proving to
(30:55):
be highly complicated, messy,and riddled with collateral
damage issues.
Which is why some scientists arestepping back and saying, hey,
if killing these cells is thisincredibly difficult and risks
harming the tissue, maybe weshouldn't be trying to kill them
at all.
SPEAKER_00 (31:10):
It's a completely different paradigm shift.
SPEAKER_02 (31:11):
Right.
What if, instead of dropping abomb on the zombie, we just
sneak up, tape its mouth shut,and walk away, let it live, but
stop it from spitting out thetoxic sludge.
SPEAKER_00 (31:20):
Welcome to the fascinating world of
xenomorphics.
SPEAKER_02 (31:23):
Okay, I love this concept.
Let's break down xenomorphics.
If I'm trying to conceptualizethis, how does the biological
mechanism differ from whatDOCTANIB does?
SPEAKER_00 (31:31):
It's a fundamental difference in the ultimate goal.
A senolytic like Dacetanib is abiochemical assassin.
Its entire singular job is tojam the survival switchboard,
trigger apoptosis, and eradicatethe physical cell entirely.
It leaves a microcrater wherethe cell used to be.
A xenomorphic, on the otherhand, is a modulator, a diplomat
(31:52):
almost.
It does not kill the cell.
Instead, it enters the senescentcell and specifically targets
the transcription pathways thatmanufacture the SEP sludge.
SPEAKER_02 (32:00):
Like shutting down the factory assembly line.
SPEAKER_00 (32:02):
Exactly.
It blocks the internal signals,often pathways like NF kappa B
or MTOR that tell the cell toproduce interleukin 6 and all
those destructive proteases.
The cell stays alive.
It remains in its state ofarrested division.
But it is completely silenced.
SPEAKER_01 (32:17):
Muzzled.
SPEAKER_00 (32:17):
Muzzled.
You halt the bystander effect,you radically drop the local
tissue inflammation, but thephysical bulk of the cell
remains perfectly intact.
SPEAKER_02 (32:24):
Okay, I have a source here that perfectly
illustrates this in the realworld.
It's about a proprietary peptidecalled OSR1.
It was developed by a longevityskincare company called OneSkin.
And their data is superinteresting because they aren't
testing this on mice.
They applied this OSR01 peptideto actual human skin samples,
like literal ex vivo skin tissuegrown in a lab.
(32:47):
And they measured the S Azomarkers before and after.
SPEAKER_00 (32:49):
And what do the transcription markers show?
SPEAKER_02 (32:51):
The OSO1 significantly reduced the levels
of interlichin 6 and CXCO1,which we know are the major
inflammatory alarm bells in theSASP.
But here is the key it did thiswithout reducing the overall
cell viability count.
It didn't kill a single cell.
Because of that, the researchersofficially classified OSO1 as a
cinomorphic, and the physicalresults were wild.
(33:12):
By just turning off the toxicsludge, they saw reduced melanin
deposits, meaning lesshyperpigmentation, fewer age
spots, and they actually saw anincrease in epidermal thickness.
The skin structurally startedacting younger, thicker, more
resilient, purely because thechemical alarm bells were
finally turned off.
SPEAKER_00 (33:28):
It is a highly elegant, highly effective
approach, especially fordermatology.
SPEAKER_02 (33:33):
But I have to ask, and I feel like anyone listening
is thinking the exact samething.
Honestly, why wouldn't we justwant to nuke them?
I get that muzzling them worksfor a cosmetic skin cream, but
internally, it feels likefinding a live bomb in your
living room, pulling the firingwires out, and then just leaving
the casing sitting on yourcoffee table forever.
(33:53):
Why leave a muzzled zombietaking up space in your body?
Shouldn't we just sweep theminto the trash and let new cells
grow?
SPEAKER_00 (34:01):
That is a highly intuitive question, and it's the
exact debate happening ingerontology right now.
But the nuke them all approachignores the sheer physical
reality of human tissuearchitecture.
I want you to think about whathappens if you have an organ
that is heavily, heavilyburdened with senescent cells.
Let's say you are 75 years old,and 15% of the cells in a
critical area of your skin, orworse, a critical area of your
(34:23):
brain, are senescent.
SPEAKER_02 (34:24):
Okay.
15% is a lot.
SPEAKER_00 (34:26):
It's a massive amount.
Now, if you come in with ahighly potent, perfectly
absorbed synolytic and yousuccessfully nuke all of them,
you have just suddenly violentlyeradicated 15% of the physical
mass of that tissue.
Yeah.
SPEAKER_02 (34:39):
Oh wow.
You're leaving holes.
SPEAKER_00 (34:41):
You're leaving microscopic, cavernous holes
everywhere.
Now, in some tissues, this isfine.
In your liver or your blood, thesurrounding healthy stem cells
can rapidly divide, fill thegaps, and the tissue regenerates
like nothing happened.
But what about tissues that donot regenerate easily?
Or at all?
SPEAKER_01 (34:59):
Like the brain.
SPEAKER_00 (35:00):
Exactly.
Neurons in the central nervoussystem are largely postmitotic.
They do not divide to replacethemselves.
If you aggressively kill offsenescent neurons or the
senescent glial cells thatphysically support the neurons,
your body might not be able toreplace them.
You can induce rapidcatastrophic structural
degradation.
You could literally acceleratedementia by trying to cure it.
SPEAKER_01 (35:21):
Wow, that's terrifying.
SPEAKER_00 (35:22):
Right.
Or take the skin.
If you kill off 15% of thedermal fibroblasts all at once,
the skin might just physicallycollapse, losing all its
structural integrity andwrinkling dramatically.
In those highly specificsensitive environments, you
absolutely do not want to reducethe overall cell count.
You need a physical bulk of thecell to maintain the 3D
(35:43):
scaffolding of the tissue.
SPEAKER_02 (35:44):
Dude, so the zombie is still holding up the wall.
SPEAKER_00 (35:47):
Yes.
It's a load-bearing zombie.
You just need it to stopscreaming and setting the room
on fire with its SASP.
SPEAKER_01 (35:53):
Yeah.
SPEAKER_00 (35:53):
That is why xenomorphics are incredibly
important.
Sometimes muzzling the zombie isthe much safer, much more viable
biological option than totaleradication.
SPEAKER_02 (36:03):
A load-bearing zombie.
That is brilliant.
It makes total sense.
You can't just knock down thepillars of a building because
they're ugly.
Okay, so we use xenomorphics fordelicate, non-regenerating
tissues.
But what about the organs wherewe do want to wipe the board
clean, like the kidneys or theliver, where we really do want
to completely eradicate thezombies, but we don't want to
rely on these poorly absorbedplant powders, and we don't want
(36:24):
the collateral damage of broadspectrum chemo drugs.
SPEAKER_00 (36:27):
Right.
If you want to clear them outsafely, you need to abandon the
small molecule pills entirely.
SPEAKER_02 (36:32):
Exactly.
Which means we are moving pastthe pharmacy and into pure
sci-fi territory.
We need precision.
We are moving from dropping dumbbombs to sending in
precision-guided munitions.
Let's look at oisinbiotechnologies.
This is a biotech startup, andtheir approach is so radically
different from DOCTINIB orphysitin.
They aren't using chemicals topoison the cells.
(36:53):
They are using suicide genetherapy delivered via a
proteolipid vehicle.
SPEAKER_00 (36:57):
Okay, you're the expert here.
Explain the physics of aproteolipid vehicle.
How does that actually work inthe bloodstream?
It's brilliant engineering.
Think of a proteolipid vehicleas a microscopic, highly
stealthy Trojan horse.
It is essentially a tinysynthetic nanoparticle bubble
made out of fats, lipids, andspecific targeting proteins.
Inside this hollow bubble, theyhide a piece of engineered DNA.
(37:20):
This bubble is injected intoyour bloodstream.
And because its outer shell ismade of the exact same lipid
material that your cellmembranes are made of, when it
bumps into a cell, it doesn'tbounce off.
It seamlessly fuses with thecell membrane, melting into it,
and safely drops its DNA payloaddirectly inside the cell.
SPEAKER_02 (37:37):
Okay, so the Trojan horse gets inside the city
walls, it drops the syntheticDNA into the cell.
What does the DNA actually do?
Does it just start makingpoison?
SPEAKER_00 (37:46):
This is the genius part, and it solves the
collateral damage problemcompletely.
The DNA they drop inside isprogrammed to be completely
inert.
It's a dormant script.
It does absolutely nothingunless it finds itself inside a
cell that is actively expressingsenescence markers.
SPEAKER_02 (38:00):
Wait, how does it know?
SPEAKER_00 (38:01):
Because of the promoter sequence, they engineer
the DNA to only activate if itdetects a specific cellular
environment.
Usually they target the P16promoter.
The P16 gene is massivelyhyperactive in senescent cells.
It's one of the main pathwaysthey use to lock their cell
cycle.
If the Trojan horse drops theDNA into a healthy normal cell,
the healthy cell's internalmachinery looks at the DNA,
(38:24):
doesn't recognize the P16trigger, and just ignores it.
The DNA harmlessly degrades.
Nothing happens.
SPEAKER_02 (38:30):
But if it drops into a zombie cell.
SPEAKER_00 (38:31):
If it drops into a zombie cell, the cell's own
road, hyperactive P16 machineryaccidentally reads the DNA
sequence.
It triggers the script.
And the script contains theexplicit overriding instructions
for the cell to commit suicide.
It forces the cell to activateCaspace 9, which triggers
apoptosis from the inside out.
SPEAKER_02 (38:48):
That is ruthless.
It literally uses the zombie'sown corrupted machinery against
it to pull the trigger.
SPEAKER_00 (38:54):
Highly targeted, highly specific.
It completely bypasses all ofthose SCP blast fields we talked
about because it's not trying tobatter the cell from the outside
with kinase inhibitors.
It's stealthily rewriting thesoftware from the inside to
command a self-destruct.
SPEAKER_02 (39:08):
Aaron Powell And their primary target right now
is chronic kidney disease, CKD,right?
SPEAKER_00 (39:12):
Yes.
The kidneys are highly, highlysusceptible to senescent cell
accumulation as we age.
And as those cells build up, theSESP sludge drives intense
fibrosis, which is essentiallyinternal scarring.
It scars the delicate filtrationsystems of the kidney until they
fail.
Currently in modern medicine,there is very little we can do
to reverse CKD.
You just manage the declineuntil you need dialysis.
SPEAKER_02 (39:33):
But Oisin tested this in mice.
SPEAKER_00 (39:36):
They did.
And the preclinical data in miceis staggering.
By repeatedly clearing out thesenescent cells using this
precision gene therapy, theysignificantly reduced the
senescent burden in the kidneys.
They physically halted thefibrosis, the kidneys started
functioning better.
And most incredibly, when theygave this to naturally aged
mice, just regular old mice, notgenetically modified ones, this
(39:58):
technology extended their medianhealthy lifespan by over 20
percent.
SPEAKER_02 (40:02):
If you extrapolate that to a human lifespan, that's
like adding 15 or 20 healthy,vibrant years to someone's life.
Not just frail years, butfunctional years.
SPEAKER_00 (40:11):
It is an astonishing number.
Now we always have to cautionthat mice are not humans.
We've cured cancer in mice athousand times.
But the precision of thedelivery mechanism, the fact
that it avoids the livertoxicity of physicin and the
broad spectrum damage ofdocetinib is what gives
researchers so much legitimatehope.
SPEAKER_02 (40:28):
And oison isn't the only team looking at precision
targeting.
There is a massive crossoverhappening right now from the
oncology world.
Let's talk about CAR T celltherapy, because anyone who
follows cancer research knowsCAR T.
It is the ultimate personalizedmedicine.
You take a patient's own whiteblood cells out of their body,
(40:48):
you take them to a lab, youbiologically reprogram them to
recognize a specific cancermarker, and you multiply them.
You basically train a million ofyour own immune cells to act
like special forces, and thenyou put them back in the body to
hunt the cancer.
SPEAKER_00 (41:01):
That's a perfect summary of CAR T.
It absolutely revolutionized thetreatment of liquid tumors like
leukemia and lymphoma.
And now researchers have had amassive realization.
If we can train the immunesystem to hunt cancer cells, why
can't we use that exact samespecial force as training to
hunt senescence cells?
SPEAKER_02 (41:19):
Right, because the whole problem is
immunosinescence.
The immune system forgot how tofind the zombies, so we just
retrain them.
But wait, how do the immunecells know which one is the
zombie?
You can't target P16 becausethat's on the inside of the
cell.
T cells only see the outside.
SPEAKER_00 (41:34):
Exactly.
They need a surface target, abeacon.
And researchers at places likeCold Spring Harbor Laboratory
discovered a unique, highlyspecific cell surface receptor
called UPR, urokinaseplasminogen activator receptor.
It's a mouthful, but whatmatters is that UPR is broadly
heavily expressed on the outermembrane of senescent cells, but
(41:56):
it is almost entirely absent onhealthy cells.
SPEAKER_02 (41:58):
So it's literally like a glowing neon sign on the
zombie's forehead.
SPEAKER_00 (42:02):
Exactly, a neon sign that says I am senescent.
So scientists engineered CAR Tcells to exclusively hunt down
anything wearing that UPIA sign.
They took these UPR-directed CART cells and infused them into
mice.
SPEAKER_02 (42:13):
And let me guess, it worked.
SPEAKER_00 (42:14):
The immune cells acted like a highly trained HIT
squad.
They rapidly and efficientlyeradicated the senescent cells
across multiple tissues.
They reversed liver fibrosisinduced by chemicals.
And incredibly, they evenextended survival in mice that
had lung cancer.
Not because the T cells attackedthe cancer directly, but because
they cleared out the senescentcells and the surrounding tissue
(42:37):
that were creating that toxic,tumor-permissive SP environment.
They cleaned up the neighborhoodand the cancer lost its
foothold.
SPEAKER_02 (42:45):
Wow.
So if we step back and look atthe whole evolution of this
field, it's incredible.
D plus Q was like dropping awide area bomb.
It gets the job done, but youmight cause some collateral
damage to your cellularswitchboards if you don't have
enough zombies to justify it.
The seating was essentially adead missile.
The warhead was good, but itburned up in the atmosphere of
the liver before it ever reachedthe target.
But these genetic Trojan horsesand cardiotherapies, that is
(43:07):
like sending in a microscopicNavy SEAL team.
Total precision, zeroing inexactly on the target, leaving
the healthy civilian cellscompletely untouched.
SPEAKER_00 (43:17):
That is exactly the trajectory the longevity field
is taking right now, movingrapidly from repurposed blunt
chemical instruments to bespoke,hyper-precise molecular
machinery.
SPEAKER_02 (43:28):
Okay, we have covered a massive amount of
ground today.
If you are listening to this,digesting all this biology,
here's the core summary of whatyou need to take away.
Cellular senescence is real.
These zombie cells and the toxicSASP sludge they pump out are a
major fundamental mechanicaldriver of why our bodies age and
why we get sick.
(43:48):
The therapies to combat thexenolytics, to assassinate them,
the xenomorphics, to muzzle theload bearing ones are incredibly
real and showing jaw droppingpromise in the lab.
But, and this is the mostimportant takeaway, we are
currently In the messy dial upinternet phase of this science.
SPEAKER_00 (44:03):
That is such an excellent way to conceptualize
it.
Dial up internet.
SPEAKER_02 (44:06):
Right.
Like you hear the screechingmodem, it connects, it
technically works, but it dropsthe call half the time.
It's slow and it's clunky.
Avoid the hype of theover-the-counter quick fixes.
Swallowing handfuls of poorlyabsorbed plant extracts is
likely not doing what theInstagram biohacker ads tell you
it's doing.
You have to be patient.
You have to wait for theprecision medicine.
(44:28):
The Navy SEAL teams are coming,but they are still in basic
training in the phase oneclinical trials.
SPEAKER_00 (44:33):
Exactly.
Protect your health through theboring proven methods, sleep,
exercise, diet, while you waitfor the biotechnology to mature.
But while we wait for thoseclinical trials to finish, I
want to leave you, the listener,with something much deeper to
think about.
Because we spent this entirehour talking about the raw
biology of extending healthspan, the proteins in the cells,
(44:54):
but we haven't talked about thepsychology.
SPEAKER_02 (44:55):
Oh, I like where this is going.
Biology versus psychology.
SPEAKER_00 (44:58):
In our stack of sources, buried beneath all the
clinical trial data, there is afascinating report from the
Nuffield Council on Bioethics.
It explores the profound ethicaland psychological considerations
of the future of aging, and theyintroduce this brilliant concept
called psychoage.
It refers to our subjectivepsychological age, how old we
(45:19):
feel in our minds, and how thatfeeling dictates our behavior.
SPEAKER_02 (45:22):
Right, because an 80-year-old thinks very
differently about their futurethan a 20-year-old does.
SPEAKER_00 (45:27):
Exactly.
Now I want you to imagine ascenario five, maybe ten years
from now.
Let's say Oisens Gene Therapy orthe Cari T therapies actually
cross the finish line.
They get FDA approval.
They work in humans safely.
And suddenly we can reliablymedically extend human health
span by 20%.
You take a targeted treatment atage 60, and suddenly your joints
(45:48):
stop aching, your brain fogcompletely clears, your
cardiovascular system operateswith the elasticity it had when
you were 40, your biologicalclock effectively stops ticking
so loudly in your ear.
SPEAKER_02 (45:59):
I mean, that sounds like the ultimate dream.
Sign me up.
SPEAKER_00 (46:01):
It does sound like a dream.
But what actually happens tohuman psychology when that
biological clock stops?
Think about it.
So much of human ambition, ourintense drive to create, to
build companies, to paintmasterpieces, to start families,
to achieve our goals, it issubconsciously heavily driven by
the ticking of that clock.
We know deeply that our time islimited.
(46:23):
Our bodies remind us every day,so we act with urgency.
SPEAKER_02 (46:27):
Art is long, life is short.
The deadline is what forces youto do the work.
SPEAKER_00 (46:31):
Exactly.
The deadline forces the action.
So here's the philosophicalquestion.
If you know with relativemedical certainty that you have
decades and decades of healthy,vibrant, pain-free life
stretching out ahead of you,does your psychological drive
fundamentally change?
Does the urgency of lifedisappear?
Do we become a society ofprocrastinators, becoming
(46:51):
complacent because there'salways tomorrow or next decade
to write that book or changecareers?
SPEAKER_02 (46:56):
That's a dark thought, like we just lose our
fire.
SPEAKER_00 (46:58):
Or conversely, does removing the subconscious terror
of physical decline and deathfinally free you?
Does taking away the anxiety ofa failing body allow you to
truly live, to take massiverisks, to learn a fifth
language, to start overcompletely at age 70 without
fear?
Does it unlock a completely newphase of human potential that we
haven't even evolved tounderstand yet?
SPEAKER_02 (47:19):
Wow.
If the biological scaffoldingholds up and suddenly we have a
clear, realistic path to ahundred or a hundred and twenty
healthy functional years, whatdo we actually do all that time?
Who do we become?
That is something for you tochew on until next time.
Popular Podcasts
Joy 101 with Hoda Kotb
Joy is essential. And it's also elusive. You can't order it, borrow it, or simply hope it into life. But now, there's a new and exciting way to start your journey toward a more joyful existence: The Joy 101 Podcast with Hoda! Best known for her Emmy-winning work and co-anchoring Today, Hoda Kotb infuses her authenticity, curiosity, and warmth into conversations with the world’s most fascinating people. Entertainment legends, sport icons, wellness experts, and everyday folks will share how they find, allow, and experience joy. Hoda will offer her own tips and takes on seeking a more balanced, harmonious life. If you're craving inspiration, support, and useful tools to maximize your joy, tune in to these candid, uplifting, and moving on-air chats. Joy after a breakup, joy as an empty-nester, joy after loss, joy as a caretaker — Hoda's new podcast will speak to you. Joy 101 with Hoda Kotb, an iHeartPodcast.
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com